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Aging is a natural, progressive and inevitable biological process characterized by a gradual 
decline of cellular function as well as progressive structural changes in many organ systems. 
These anatomic and physiological changes delineate the process of senescence, a term that 
describes more predictable age-related alterations as opposed to those induced by 
diseases. Like other organ systems, the kidneys also go through the process of normal 
senescence, including both anatomical and physiological changes. These changes in a 
normal aging kidney are distinct from those in kidney diseases such as diabetic nephropathy 
or nephroangiosclerosis, which are relatively common in elderly. Nonetheless, it is often 
challenging to distinguish an inevitable organ-based senescence from a disease-mediated 
structural and functional changes in the elderly. Yet, it is important to emphasize that age-
related diseases, when superimposed on those of normal senescence, can significantly alter 
the rate of functional decline, exhaust renal functional reserve and predispose these 
patients to cardiovascular complications or even death, particularly when a frank chronic 
kidney disease (CKD) is manifested. The association between CKD and cardiovascular 
disease (CVD) is now largely acknowledged. Cardiovascular mortality is about twice as high 
in patients with stage 3 CKD (estimated glomerular filtration rate (GFR) 30–59 mL/min/1.73 
m2) and three times higher at stage 4 (GFR 15–29 mL/min/1.73 m2) compared to individuals 
with normal kidney function (1). In end-stage kidney disease (ESKD) dialysis patients, the 
mortality risk becomes 10 to 30 times higher than in the general population (2). 
Most of the traditional CVD risk factors, such as older age, diabetes mellitus, systolic 
hypertension, left ventricular dysfunction (LVH) and low high-density lipoprotein (HDL) 
cholesterol, are highly prevalent in CKD. However, although the cardiovascular risk 
conferred by these factors may somewhat parallel the relationships described in the general 
population, several cross-sectional studies have suggested that the Framingham risk 
equation does not fully capture the extent of CVD risk in subjects with CKD (3). Discovering 
new risk factors or prognostic indicators is therefore of foremost importance to refine 
outcome prediction and drive therapeutic management in this particular disease setting. 
Similar to the decline in organs’ function, it is well known that an impairment in physical 
capacity represents a major feature of the senescence process. A reduced physical activity, 
poor fitness or even mobility impairment of various degrees are frequent characteristics of 
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elderly individuals. Although no amount of physical activity can stop the biological aging 
process, regular exercise can counteract some of the adverse physiological, psychological, 
and cognitive consequences of aging (4). Aging and physical inactivity are primary and 
indirect risk factors for a long list of adverse chronic conditions (5), whereas increasing 
physical activity from midlife to old age results in reduced rates of chronic disease and 
death. Due to fatigue and muscle weakness, patients with CKD also have low levels of 
physical activity. Such a reduced fitness capacity is noteworthy as it is associated with 
deconditioning and muscle wasting, declining kidney function and an increased risk of 
comorbidities such as cardiovascular disease. Thus a downward spiral between disease, 
disuse and deconditioning exists leading to a reduced quality of life, increased 
hospitalization rates and mortality (6).  
In this thesis, I aimed at summarizing the cross-linked relationships between aging, physical 
activity and chronic kidney disease when looking at the exceedingly high cardiovascular risk 
which characterizes individuals with impaired renal function. In the first part, I focused on 
the myriad of epidemiological, pathophysiological and functional aspects characterizing 
normal and pathological renal senescence through a systematic approach to the existing 
literature, throwing also an eye on futuristic strategies to retard kidney aging (Chapter 2). 
Attention is paid to pulmonary hypertension (PH) as an emerging but still underestimated 
risk factor for mortality that worsens cardiovascular outcomes in the CKD setting. First, I 
summarized current evidence on the diagnostic and prognostic implications of this issue 
(Chapter 3) and then presented findings from a multicenter clinical investigation specifically 
aiming at testing the predictive role of PH in a large cohort of early CKD individuals with 
respect to hard patients’ endpoints (Chapter 4). In the second part, I focused on physical 
activity and its impact on cardiovascular outcomes, particularly in aging and advanced CKD. 
To provide insights into the physiology of vascular pressor responses handgrip exercise 
across different age strata was performed in an experimental pilot trial of healthy 
individuals (Chapter 5). Thereafter, ESKD patients, a high risk population that is also 
acknowledged to be exceedingly sedentary (7), were analysed to explore the relationships 
between poor physical performance/impaired mobility and cardiovascular outcomes 
Chapter 1__________________________________________________________________________ 
 
12 
 
(Chapters 6 and 7). These latter points have been addressed by analyses of the EXerCise 
Introduction To Enhance Performance in Dialysis (EXCITE) study.  
This study is a large multicenter, randomized trial designed to evaluate if a model of 
intervention based on a low-grade physical program prescribed in the dialysis unit and 
performed at home can modify the physical activity and quality of life, reduce the risk of 
cardiovascular and all-causes mortality, non-fatal cardiovascular events and vascular access 
failure in dialysis patients (8).  
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ABSTRACT 
As for the whole human body, the kidney undergoes age-related changes which translate in 
an inexorable and progressive decline in renal function. Renal aging is a multifactorial 
process where gender, race and genetic background and several key-mediators such as 
oxidative stress, the renin-angiotensin-aldosterone (RAAS) system, impairment in kidney 
repair capacities and background cardiovascular disease play a significant role. Features of 
the aging kidney include macroscopic and microscopic changes and important functional 
adaptations, none of which is pathognomonic of aging. The assessment of renal function in 
the framework of aging is problematic and the question whether renal aging should be 
considered as a physiological or pathological process remains a much debated issue. 
Although promising dietary and pharmacological approaches have been tested to retard 
aging processes or renal function decline in the elderly, proper lifestyle modifications, as 
those applicable to the general population, currently represent the most plausible approach 
to maintain kidney health. 
 
Keywords: renal aging, renal senescence, chronic kidney disease, renal function decline, 
aging processes. 
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1. INTRODUCTION 
Human lifespan has substantially increased over the last century and the projected increase 
of elderly people over the next two future decades is impressive. Persons aged 65 years or 
more were 420 million in 2000 (1). By 2030, the number of these individuals is expected to 
be 550–973 million (1). By that date, elderly people will account for approximately 20%, 
24.8% and 33% of the global population in the US, China and Europe respectively, exceeding 
the number of children below 15 years (2). The average age is now 76.5 years in 
economically developed- and 65.4 years in economically developing-countries (2). 
Population based studies documented that impaired renal function is common in the 
elderly. In the US population, renal dysfunction has a 15% prevalence in persons older than 
70 years (3). In the third National Health and Nutrition Examination Survey (NHANES III), 
35% of the elderly population had stage 3 chronic kidney disease (CKD) (4). The prevalence 
of the most severe CKD stage (stage 5 or end-stage kidney disease; ESKD) is age-dependent 
(4, 5). In the United States Renal Data System (USRDS) the prevalence of the age-stratum 
65-74 years is 11% and 14% for those older than 75 years (6) and similar findings have been 
reported also in European cohorts (7-9). In this systematic review, we describe the main 
anatomical and functional changes in the kidney associated with senescence and will 
provide updated information on the main molecular and biological pathways involved in 
renal aging. The criteria adopted for literature search and selection for this review are 
detailed in Figure 1.  
 
Figure 1. Review criteria 
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2. EPIDEMIOLOGY OF RENAL FUNCTION DECLINE WITH AGE 
Changes in renal function associated with aging have been estimated in 9 cross-sectional 
and in 3 cohort studies. In these studies, the annual average GFR reduction ranged from 0.4 
to 2.6 mL/min (Table 1). The cross-sectional nature of most of these analyses and the fact 
that four of them were performed in living kidney donors (10-13), a highly-selected 
population where the absence of CKD and other co-morbidities is a pre-requisite for kidney 
donation, limits the generalizability of these findings and leaves open the question whether 
the decline in renal function is an inexorable process.  
In studies based on inulin clearance performed in the fifties in a group of 70 men, including 
healthy volunteers but also hospitalized patients affected by hypertension, cancer, 
arteriosclerosis and various infective diseases, the GFR was by the 46% lower in the very old 
(90 years) as compared to the young people (14) and these findings were confirmed in a 
survey based on urea clearance (15). In the Baltimore Longitudinal Study of Aging (BLSA) 
(16), a longitudinal study based on serial creatinine clearance measurements in 254 men 
without kidney disease or hypertension, the average decline in GFR was 0.75 mL/min/year, 
an estimate very close to that described in a recent cross-sectional study in 1203 living 
kidney donors (0.63 mL/min/year) (13). In the Baltimore study, the rate of GFR loss was 
tripled (~1.51 mL/min) in subjects aged 40-80 years as compared to subjects aged 20-39 
years (0.26 mL/min). Similar observations were reported more recently in a longitudinal 
study in healthy Chinese people (17). Both in the Baltimore (16) and in the Chinese (17) 
study the GFR remained constant overtime in 36% and 44% of subjects respectively. In the 
Bronx longitudinal age study (18, 19) in very elderly subjects, just a small increase in serum 
creatinine occurred after 3 years in long term survivors and similar observations were 
reported in a subgroup of 31 subjects with mildly raised serum urea at baseline, suggesting 
that renal function decline may not be an obligatory consequence of the aging process. In a 
cross-sectional analysis of the BLSA study (20) focusing on 548 healthy subjects, creatinine 
clearance was 140 ml/min/1.73m2 at age 30 to fall to 97 ml/min/1.73m2 at age 80. In the 
inception cohort of the Nijmegen Biomedical Study (21), including 869 apparently healthy 
persons aged>65 years, the annual GFR decline (as estimated by the MDRD185 formula) was 
approximately 0.4 mL/min/year. In a mixed population of adults aged≥65 years including 
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participants with major co-morbidities (CKD included), the InCHIANTI study, creatinine 
clearance estimated by the Cockcroft formula showed a 2.6 mL/min/year decline over a 3-
year follow up (22). Overall, these studies clearly document that on average renal function 
declines overtime but also show that in about one third of elderly individuals the GFR 
remains remarkably constant. 
 
Table 1. Main studies on renal function decline with aging 
Author Year Methods Results 
Davies and Shock 
(15) 
1950 -Cross-sectional analysis of a 
miscellaneous population of 70 
men aged 25 to 89 years including 
healthy subjects and hospitalized 
patients.  
-mGFR by inulin clearance. 
-Linear 46% decline in mGFR from 123 
(at the age of 30)  to 65 (at the age of 
89) mL/min/1.73 m2 . 
Smith et al. (14) 1951 -Cross-sectional analysis of 
general population.  
-Renal function measured as urea 
clearance. 
-Decrease in urea clearance from 100% 
at the age of 30 years to 55% at the age 
of 89 years. 
Rowe et al. (20) 1976 -Cross-sectional analysis of an 
inception cohort of 548 men (aged 
20-80 years) from the BLSA.  
-eGFR by creatinine clearance. 
-Progressive linear decline (31%) in 
eGFR from 140 (at age 30) to 97 (at age 
80) mL/min/1.73 m2. 
Lindeman et al. (16) 1985 -Prospective study of an inception 
cohort of 254 men (aged 20-80 
years) without kidney disease 
from the BLSA followed over 5 to 
14 years. 
-eGFR by creatinine clearance. 
-The mean decrease in eGFR was 0.75 
ml/min/year.  
-Annual eGFR changes were different 
between the age class 20-39 (0.63 
mL/min/year) and 40-80 (1.51 
mL/min/year). 
-36% of all subjects followed had no 
absolute decrease in renal function.  
-A small group of patients showed a 
statistically significant increase in 
creatinine clearance with age. 
Feinfeld et al. (18, 
19) 
1995 -Prospective study of 141 very 
elderly subjects followed over 6 
years. 
-Renal function assessed by BUN 
and serum creatinine. 
-Small but significant decline in BUN and 
creatinine at 3 years, which persisted at 
6 years.  
Rule et al. (11) 2004 -Retrospective analysis of 365 
potential living kidney donors. 
-mGFR by iothalamate clearance, 
eGFR by MDRD and Cockroft-Gault 
formulas. 
-Men at the age of 20 years had an 
estimated mean GFR of 129 mL/min 
that declined by 4.6 mL/min/decade.  
-Women at the age of 20 years had a 
mean GFR of 123 mL/min that declined 
by 7.1 mL/min/decade. 
Fehrman-Ekholm et 
al. (12) 
2004 -Cross-sectional analysis of 52 
elderly "healthy" persons aged 70-
110 years. 
-mGFR decreases by approximately 1.05 
ml/min per year in very old persons. 
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 -mGFR by iothalamate, eGFR by 
Cockroft-Gault, MDRD and Walser 
formulas. 
Wetzels et al. (21) 2007 -Cross-sectional study of an 
“healthy” inception cohort of 3732 
subjects  from the Nijmegen 
Biomedical Study, of whom 869 
were elderly (age>65 years). 
-eGFR by MDRD. 
- eGFR declined by 0.4 mL/min/year 
Lauretani et al. (22) 2008 -Cross-sectional and prospective 
analysis (3 years follow-up) of 931 
adults (aged≥65 years) from the 
InCHIANTI study. 
-eGFR by Cockroft-Gault formula. 
- eGFR declined by 2.6 mL/min/year 
Poggio et al. (10) 2009 -Cross-sectional analysis of 1057 
prospective kidney donors.  
-mGFR by iothalamate clearance.  
-mGFR was reduced by 1.49+/-0.61 
ml/min per 1.73 m2 per decade of 
testing. 
-Significant doubling in the rate of GFR 
decline in donors over age 45 as 
compared to younger donors. 
Rule et al. (13) 2010 -Cross-sectional analysis of 1203 
adult living kidney donors. 
--mGFR by iothalamate clearance, 
eGFR by MDRD and Cockroft-Gault 
formulas. 
- reduction in mGFR by 6.3 mL/min per 
decade 
Jiang et al. (17) 2012 -Prospective study of middle-aged 
and elderly 245 healthy individuals  
evaluated over a 5 years follow-
up. 
-eGFR by creatinine clearance 
-eGFR decreased from 98.1+/-15.6 to 
90.4+/-17.3mL/min/1.73m2. 
-43% of participants did not experience 
a decline in eGFR during follow-up. 
 
BLSA: Baltimore Longitudinal Study of Aging; BUN: Blood Urea Nitrogen; eGFR: estimated glomerular filtration 
rate; mGFR: measured glomerular filtration rate; MDRD: modification of diet in renal disease (formula). 
 
3. ISSUES WITH ASSESSMENT OF RENAL FUNCTION IN THE ELDERLY 
Because sarcopenia and body weight loss reduce the daily generation of creatinine and 
creatinine levels are influenced by protein intake and hydration, these factors concur in 
making serum creatinine a suboptimal indicator of renal function in the elderly (23). The 
reference range for creatinine considered as normal in the healthy young is inappropriately 
high in the elderly and serum values in the upper normal range may underlie early renal 
dysfunction (24). In 20 years old individuals a creatinine value of 1 mg/dL may correspond 
to an estimated GFR of 120 mL/min while the same value in 80 years-old persons might 
reflect an eGFR of 60 mL/min (25-27). Traditional formulas for GFR estimation based on 
serum creatinine are notoriously unreliable in the elderly, particularly in the presence of 
multiple co-morbidities (28, 29). In old subjects, GFR is systematically underestimated by 
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the Cockcroft-Gault (CG) formula (30, 31). The Modification of Diet in Renal Disease (MDRD) 
MDRD equation is generally considered more accurate than the CG to estimate GFR in old 
people (32). However, like the CG formula, the MDRD equation has not been specifically 
validated in the elderly and the discordance of estimates between these two formulas is 
such that the MDRD GFR may be by the 60% higher than the CG-GFR in patients over 65 
years (33). In a study involving 100 individuals aged 65-111 years no correlation was found 
between the two formulas (34). In the elderly cohort of the InCHIANTI study, creatinine 
clearance <60 mL/min calculated by the CG formula predicted all cause and cardiovascular 
mortality while the MDRD formula did not (35). In a study comparing the most recent three 
CKD Epidemiology Collaboration (CKD-EPI) formulas implementing creatinine (CKD-EPI Cr), 
cystatin-C (CKD-EPI Cys) or both (CKD-EPI Cr-Cys) in 394 elderly subjects with median age of 
80 years (36), these formulas appeared less biased and more accurate than the MDRD Study 
equation but no equation achieved sufficient accuracy when tested against the golden 
standard (GFR measured by Iohexol). Other formulas such as that proposed by Keller (37) 
and the HUGE (hematocrit, urea and gender) formula (38) apparently improve the precision 
of GFR estimation in the elderly but neither of these has yet been externally validated. 
Serum cystatin measurement, especially when compared with reference values adjusted 
for age, represents a promising marker to measure renal function in the elderly (39) but 
cystatin-based formulas are not superior to the MDRD equation for estimating renal 
function in old people with GFR<60 mL/min/1.73m2 (36). Nevertheless, formulas based on 
cystatin-C predict morbidity and mortality better than creatinine-based equations (40), a 
phenomenon likely depending on the fact that serum cystatin-C in part reflects 
inflammation, i.e. a strong predictor of clinical outcomes in the elderly (41). The Berlin 
Initiative Study (BIS)-1 (creatinine-based) and the BIS-2 (cystatin-based), have been recently 
developed in a cohort of 610 individuals aged 70 years or older with no or mild-to-
moderately reduced kidney function (GFR <60 mL/min per 1.73 m2) using Iohexol plasma 
clearance as golden standard (42). Interestingly, the BIS-2 equation yields the smallest bias 
followed by the creatinine-based BIS-1 and Cockcroft-Gault equations, while all the other 
formulas overestimate to an important extent the golden standard. These formulas are of 
obvious relevance but still lack external validation in other cohorts and, most importantly, 
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in different ethnicities. Kidney disease improving global outcomes (KDIGO) guidelines set at 
60 mL/min/1.73 m² the GFR threshold below which renal function should be considered as 
clearly impaired (43). As this universal cutoff does not take into account age, it is much 
debated whether healthy elderly subjects with a GFR in the 45-60 mL/min/1.73 m² range, 
particularly in the absence of proteinuria and urine abnormalities, should really be 
considered as “diseased” or not (44). Considering these subjects as affected by CKD may 
allow increased cardiovascular and renal surveillance but may engender harm and 
increased cost because of inappropriate and over-diagnosis of CKD in low risk elderly. As for 
other parameters, such as blood pressure and serum glucose, perfect thresholds to 
distinguish between safe and risky values do not exists. However, thresholds can be useful 
for treatment recommendations and for the identification of subpopulation at high risk of 
complications. In the CKD-EPI consortium meta-analysis (45), individuals >65 years with a 
GFR 45-59 mL/min/1.73 m2 had a 44% excess risk for cardiovascular death as compared to 
those with GFR falling in the “normal” range (>90 mL/min/1.73 m2). In this meta-analysis 
there was no effect modification by age on the cardiovascular risk associated with reduced 
GFR. In elderly individuals aged ≥75 years with GFR 45-59 mL/min/1.73 m2 the risk for end 
stage kidney disease was similar to that found in individuals aged 18–54 years with the same 
GFR, i.e., four times higher than that in individuals of the same age-categories and a GFR=80 
mL/min/1.73 m2 (46). No classification system is perfect and clinical judgment is important, 
particularly around the diagnostic thresholds. Therefore, when evaluating the GFR in the 
elderly, clinicians should consider co-morbid conditions, life expectancy and the time-
trajectory of GFR. Renal senescence is a complex, multifactorial process characterized by 
anatomical and functional changes accumulating during life span. Several factors, spanning 
from the genetic background to exposure to chronic diseases and environmental factors 
generate a “multi-hit” scenario where the renal phenotype of elderly individuals shows high 
inter-individual variability (Figure 2 and 3). 
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Figure 2. Main mechanisms leading to renal senescence 
 
Figure 3. Macroscopic and microscopic changes in the aging kidney and risk factors  
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4. FACTORS ASSOCIATED WITH RENAL AGING 
 
4.1 Gender 
In experimental models, male gender enhances the age-related decline in renal 
function (47, 48). Accelerated GFR loss in males is androgen-dependent (48). Castration 
in mice limits reno-vascular aging (49) while therapy with estrogens may prevent this 
phenomenon (50). Studies of the effect of aging on renal function and anatomy abound 
but mechanistic knowledge on gender-dependent influence on this phenomenon is 
limited (51). 
 
4.2 Race 
Black race is an established risk factor for kidney dysfunction and for the risk of 
progression to end stage kidney failure (52, 53), particularly in diabetic patients (54). 
African descent is strongly associated with the risk of hypertensive nephrosclerosis (55).  
 
4.3 Genetics 
The genetic background plays a major role in renal senescence and genotypes exist 
which regulate the number of nephrons during life (56). Epigenetics - the process 
whereby neutral cells evolve into highly differentiated cells to constitute specialized 
tissues- has a prominent role in kidney aging. Regulatory genes and post-transcriptional 
processes, such as acetylation and methylation, are crucial for the control of the 
differentiation of kidney cells and for maintaining cell function during life span. In a rat 
model of normal aging (57), there is de novo glomerular expression of proteins which 
remains silenced in the young glomerulus. Accelerated renal aging including diffuse 
glomerulosclerosis and interstitial fibrosis occurs in differentiated podocytes after 
manipulation of methylation pathways (58). Fusion of foot processes and 
disorganization of foot structures in podocytes as well as proteinuria are hallmarks of 
aging kidneys in the rat and these alterations set the stage for glomerular rarefaction 
and functional decline. Spontaneous gene mutations in somatic and mitochondrial DNA 
accumulate with normal aging in kidney cells (59). Premature aging in the progeria 
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syndrome is characterized by focal renal scarring, glomerulosclerosis, tubular atrophy 
and interstitial fibrosis and associates with mutations in genes involved in DNA repair, 
transcription and replication (60). Functional genomics studies showed that over 500 
genes are differently expressed in human kidneys across age-strata encompassing 
neonate’s (8 weeks) and elderly’s kidneys (88 years). Kidneys of elderly individuals 
overexpress proteins involved in the immune response, inflammation, extracellular 
matrix synthesis and turnover while under-express genes involved in oxidative 
processes, lipid and glucose metabolism and collagen degradation (61). In another 
study, more than 900 different age-dependent genes were identified and the 
expression of these genes changed in parallel in the cortex and in the medulla (62). 
Genes that impact upon the aging process and influence life span have been identified 
(63). However, only some of these seem to be involved in kidney aging. The senescence 
marker protein (SMP) 30-knockout mouse displays accumulation of lipofuscin and 
electron-dense material and lysosomial enlargement in the proximal tubules, which are 
alterations peculiar to kidneys of elderly individuals (64). Polymorphisms in the alpha-
adducin gene predicted renal function decline in a population-based study in 
apparently healthy Chinese people (65). In vivo, senescent renal cells, particularly in the 
renal cortex, express high levels of cellular proliferation inhibitors, such as p16 and p27 
(66), and the expression of these proteins goes along with the severity of age-associated 
glomerulosclerosis, tubular damage and interstitial fibrosis (67). The target of 
rapamycin (TOR) is a highly conserved gene pathway modulating the influence of 
nutrients on life span (68). Selective TOR-inhibition dramatically increases life span and 
this effect is prevented by caloric restriction (69). TOR expression increases with age in 
rat kidneys, particularly so in mesangial cells, and the inhibition of this pathway by 
rapamycin attenuates the aging-related phenotype in this model (70). The sirtuins 
(SIRT), a gene family homolog of the Silent information regulator 2 (Sir2) gene (71), are 
also implicated in renal aging. Sir2, another highly conserved longevity gene, is 
implicated in nutrient-dependent changes in life span (72) as well as in the prevention 
of DNA damage (73). SIRT-6 knock-out rats are characterized by premature aging in 
various organ systems including the kidney (74). SIRT-1 over-expression promotes 
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antifibrotic and antiapoptotic effects in renal interstitial cells and caloric restriction 
slows-down kidney ageing by enhancing SIRT-1-mediated mitochondrial autophagy in 
mice (75). Klotho is perhaps the most powerful "aging-suppressor" gene (76). The 
Klotho knock-out mouse exhibits aging-related diseases like atherosclerosis, 
osteoporosis, vascular and tissue calcifications and chronic kidney disease (77) and 
genetic polymorphisms in the Klotho gene have been associated with altered life span 
(78), accelerated vascular disease (79) and osteopenia (80). Klotho operates in concert 
with FGF-23 because the main receptor for this growth factor, the FGF receptor, is 
activated by FGF-23 only in the presence of Klotho in most tissues (81). In the kidney, 
Klotho is predominantly expressed in the distal convolute tubule. Furthermore, Klotho 
exerts a series of potentially nephroprotective actions including: 1) reduction of 
oxidative stress via inhibition of the insulin/IGF1 signaling and induction of the 
manganese superoxide dismutase (82); 2) fine-tuning of calcium-phosphorus 
homeostasis by down-regulation of vitamin-D synthesis and phosphaturia (83); 3) 
modulation of calcium channel activity in renal tubular cells (84); 4) regulation of 
endothelium-dependent vascular reactivity (85). Sustained oxidative and metabolic 
stress (85), angiotensin-II (AT-II) (86) and chronic kidney disease (87) down-regulate 
Klotho m-RNA expression. Transfection of the Klotho gene attenuates tubular-
interstitial fibrosis and vascular wall thickening in renal vessels induced by chronic AT-
II stimulation (88). Thus, Klotho hypo-regulation might at least in part explain the link 
between renin-angiotensin system and renal senescence (see below). Telomeres, the 
nucleoprotein complexes located at the end of chromosomes which serve to prevent 
the fusion and degradation of chromosomes, are synthetized by the enzyme 
telomerase. Kidney cells do not express the enzyme telomerase (89). Therefore, in 
these cells telomeres shorten progressively after each cell division, a process triggering 
cellular and organ senescence (90). In the human kidney, telomeres shortening 
increases with age and is more rapid in the cortex (91). Telomerase-deficient mice show 
reduced glomerular, tubular and interstitial cell proliferative capacity and limited ability 
to recover after acute kidney injuries (92). MicroRNAs (miRNAs) are fundamental 
modulators of cell function which regulate important biological events like cell-
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differentiation and apoptosis. Global disruption of miRNAs in mice is associated with 
rapidly progressive chronic kidney disease (93). However, studies of renal aging based 
on selective manipulation of the m-RNA system are lacking and the possibility of 
interfering with kidney senescence at m-RNA level is still little explored. 
 
4.4 Oxidative stress and the nitric oxide system 
Free-radicals generation increases with lifespan (94). A substantial increase in kidney 
levels of oxidative stress markers like F2 isoprostanes, advanced glycosylation end-
products (AGEs) and their receptors (RAGEs) occurs in the aging kidney (95). As to the 
AGE-RAGE system, it was found that aging also de-regulates kidney expression of AGE-
R1, a receptor preventing AGEs-mediated injury (96). AGEs and circulating RAGEs are 
independently associated with decreased renal function and predict GFR decline in 
elderly community-dwelling women (97). In a secondary analysis of the BLSA cohort, 
serum levels of L-carboxymethyl-lysine (CML), one of the main AGE products, were 
independently associated with CKD and eGFR (98). AGEs promote degradation of the 
hypoxia-inducible factor (HIF)-1α, thereby limiting the response of renal cells to 
hypoxia. This phenomenon attenuates the secretion of EPO and the release of VEGF, a 
growth factor crucial for angiogenesis (99). AGEs and other oxidants reduce telomeres 
length and cell lifespan (see above) (100). Furthermore, AGEs are powerful inhibitors of 
Nitric oxide (NO)-synthase (NOS) activity in renal tubular cells (101, 102). Reduced NO 
bioavailability plays a major role in the structural and functional adaptations of the 
aging kidney. NOs inhibition by L-NAME produces a stronger vasoconstriction in old 
than in young renal vessels (103, 104), suggesting that endogenous NO production is of 
particular relevance for the control of renal circulation in aging animals. In aging rats, 
total body NO generation is reduced (103, 105), particularly so in the endothelium of 
peritubular capillaries (eNOS), suggesting that the tubular-interstitial ischemia and 
fibrosis typically associated with renal senescence is at least in part causally related to 
oxidative stress-mediated NOS inhibition (106). Female aging rats show relatively 
conserved levels of eNOS in renal capillaries (107) and neuronal (n)NOS in renal cortex 
(108) as compared to aging male rats, a phenomenon depending on the stimulatory 
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effects of estrogens on eNOS synthesis. Renal microvasculature is particularly sensitive 
to the vasodilator effect elicited by NO, a response fundamental for the control of renal 
blood flow and pressure-natriuresis (103, 109). The endogenous inhibitor of NOS 
Asymmetric dimethylarginine (ADMA) accumulates in aging rats (105) and high ADMA 
appears to be involved in telomeres shortening (110). In elderly patients, high ADMA is 
a strong predictor of death and cardiovascular events (111). Notably, this methyl-
arginine may be an important effector of the age-related decrease of renal perfusion 
because high circulating ADMA levels go along with reduced renal perfusion in old 
people (112). Oxidative damage derives mainly from free radicals generated during 
metabolic processes at cell level. However, high dietary oxidant load with diet may 
contribute as well. Studies based on the ARIC cohort documented that subjects with 
scavenger receptors defects and high-fat diets develop atherosclerosis and severe 
impairment in kidney function (113). In the rat, a diet enriched of antioxidants (such as 
vitamin-E) reduces kidney RAGEs and F2 isoprostanes levels and increases the GFR by 
the 50% (95). Similarly, caloric restriction in aging rats increases kidney levels of 
ceruloplasmin, a powerful anti-oxidant produced by parietal epithelial cells of the 
Bowman’s capsule in response to aging (114). Lipofuscin, a complex found in the cytosol 
of aging cells, is formed by free-radicals damaged proteins and fats. This complex, which 
is resistant to degradation, substantially impairs mithocondrial function (115). In rat 
models, lipofuscin accumulation in the kidney is linearly related with age and lipofuscin 
cell levels are 28-fold higher in very old as compared to very young rats (116).  
 
4.5 Angiotensin-II 
Angiotensin II (AT-II) regulates a variety of biological functions within the kidney 
including vascular tone, aldosterone release, tubular sodium reabsorption and 
sympathetic nerve stimulation. In addition, this peptide has important effects on cell 
plasticity in the kidney because it induces fibroblast differentiation into myofibroblasts, 
vascular hypertrophy, mitogenesis and promotes the release of various cytokines and 
growth factors (such as TGF-β1) (117). AT-II receptors with opposite vascular effect 
exist. Indeed, the angiotensin receptor-1 (ATR)-1 mediates vasoconstriction while ATR-
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2 promotes NO/cGMP-mediated vasodilatation (118). In addition, ATRs stimulation by 
AT-II via the MAPK and ERK pathways leads to endothelial senescence and triggers 
endothelial and muscle cells apoptosis (119, 120). ATR-1 in the kidney are more 
abundant than ATR-2. During lifespan, the number of ATR-2 increases, which would 
favor renal vasodilation. However, due to the reduced renal flow and the attenuated 
NO-mediated vasodilatation discussed before, in the elderly the renal response to 
angiotensin-II is a sustained vasoconstriction (121). Furthermore, ATR-1 stimulation 
promotes mithocondrial damage and reactive oxygen species production, both of 
which in turn trigger age-related vascular changes (122). In the ATR-1 knockout mice, 
oxidative stress is markedly reduced in the kidney and in the hearth and renal tubular 
cells show a higher number of mithocondria as compared to wild-type controls (123). 
Of note, ATR-1 knockouts also outlive the wild-type controls by 26% and this increase 
in lifespan has been attributed to an up-regulation in the kidney of genes associated 
with survival (such as the sirtuin-3 or the NAMPT). Accordingly, ATR-blockade by 
selective inhibitors effectively improves renal function and vascular structure in aging 
rats (117).  
 
4.6 Impairment in kidney repair ability 
Cell proliferation is crucial for normal tissue turnover and for tissue regeneration. In the 
adult kidney less than 1% of renal cells maintain proliferating potential and this fraction 
further declines with aging (124). Such phenomenon is multifactorial in nature and it is 
often defined as “cellular senescence” to differentiate irreversible and specific morpho-
functional changes associated with physiological cellular aging from other forms of cell 
cycle arrest. In aged mice kidneys, a clear age-dependent decline in the proliferative 
potential of proximal tubular cells occurs after ischemia/reperfusion injury (125), a 
phenomenon secondary to modifications of various cell-cycle regulators and to 
enhancement of apoptosis. The cyclin-independent kinase (CDK) inhibitor p16INK4A, a 
powerful blocker of the cell-cycle, is up-regulated in epithelial and interstitial cells of 
aging mouse and in human kidneys as well (89, 126). Similarly p21, a CDK-inhibitor 
which induces proliferative arrest, apoptosis and cellular hypertrophy, increases with 
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age in rats (127). Both p16INK4A and p21 promote renal tubular senescence by enhancing 
telomeres shortening (91) and by upregulating the activity of senescence-related 
enzymes, such as β-galactosidase (89). The Caspase family includes several cysteine 
protease involved in apoptosis induction (128). Caspases 3,9 and the caspase-9 
activator cytochrome-c are upregulated in the kidney of aging rodents (128, 129) as it 
is the pro-apoptotic protein Bax (125). Conversely, the expression of Bcl-2, a powerful 
apoptosis inhibitor, is reduced in renal tissue of aging rats (125). Overall, multiple 
alterations in systems controlling apoptosis explain the very high apoptosis rate in aging 
kidneys (106, 129). As previously alluded to, this pro-apoptotic pattern can be largely 
prevented by a low-calories diet adopted at young age (130). Growth factors are key 
players in kidney repair and an age-driven impairment in the pathways activated by 
these factors has been advocated to explain the inadequate regenerative capacity of 
the aging kidney (131). The expression of factors promoting cell recruitment and cell 
proliferation such as the epidermal growth factor (EGF), the insulin-like growth factor 
(IGF)-1 and the vascular endothelial growth factor (VEGF), decline in an age-dependent 
fashion (132-134) while the expression of pro-fibrotic factors like transforming growth 
factor (TGF)-β and integrin-linked kinase (ILK) increases (127, 135). A variety of other 
factors have been implicated in the impaired repair ability of senescent kidneys. The 
potential role of these factors in kidney aging was reviewed in detail elsewhere (136).  
 
4.7 Cardiovascular disease and risk factors 
The age-related decline in renal function is amplified in subjects with pre-existing 
cardiovascular disease and/or risk factors. In a cohort study of 1456 elderly individuals, 
the components of the metabolic syndrome and insulin resistance predicted the risks 
of prevalent and incident CKD (137). Hypertension, a classical age-dependent disease 
(138, 139), associates with typical changes in renal structure and function (140). High 
BP amplifies age-related vascular stiffness and atherosclerosis and vice versa (141). 
Endothelial dysfunction, disturbed regulation of the renin-angiotensin system and 
increased sympathetic tone are critical factors at the hypertension-renal ageing 
interface. Furthermore, due to age-related tubular-interstitial alterations, elderly 
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subjects are salt-sensitive, i.e. predisposed to aggravation of renal damage by 
hypertension-dependent and independent mechanisms when exposed to excessive salt 
intake (142). In this respect, it is well documented that salt-restriction programs in the 
elderly allows better blood pressure control and improve clinical outcomes (143).  
Even though the causal nature of the link of aging with hypertension, arterial stiffness 
and renal dysfunction is reasonably well established, in the healthy elderly cohort of 
the BLSA study BP failed to predict the age-associated decline in creatinine clearance 
(144) while carotid intima-media thickness had no prognostic value for renal function 
in a community cohort in China (145). In the Italian Longitudinal Study on Ageing (ILSA) 
cohort in 2981 subjects aged 65-84 years with normal renal function (146), renal 
function loss as defined by an increase in serum creatinine >26.5 micromol/L associated 
with current smoking status (OR=2.3; 95% CI=1.0-5.3), fibrinogen levels>3.5 g/l 
(OR=2.2; 95% CI=1.6-3.3), diabetes (OR=1.8; 95% CI=1.1-2.8) and systolic hypertension 
(OR=1.6; 95% CI=1.0-2.6). Similarly, in the Cardiovascular Health Study (147, 148) 
smoking, systolic blood pressure, internal carotid artery thickness and retinal 
microvascular abnormalities independently predicted renal function decline overtime. 
Similar findings were reported in two large community-based cohort studies (149, 150) 
and in a recent study we briefly alluded to before (17). The severity of systemic 
atherosclerosis has been indicated as one of the major determinants of age-related 
glomerulosclerosis and decline in renal function (151).  
 
5. STRUCTURAL AND FUNCTIONAL CHANGES IN THE AGING KIDNEY 
The main anatomic and functional modifications which characterize the aging kidney 
are summarized in Figure 3 and Table 2. Kidney mass progressively increases from birth 
to the fourth decade of life, peaking at 250-270 g (152) and gradually regresses 
thereafter at a 10% reduction rate per decade (153-155) (Figure 4). In the seventh and 
eighth decades, kidney mass is therefore at least 20-30% less than in the fourth decade 
(156) and the reduction is more pronounced in the renal cortex than in the medulla 
(155, 157). As expected, kidney size follows the same temporal trend (153). In a series 
of 1957 potential kidney donors undergoing pre-donation renal imaging studies by 
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computer tomography kidney aging was accompanied by parenchymal calcifications 
and by a rising prevalence of simple renal cysts (158). From a microscopic point of view, 
the aging kidney displays glomerular, vascular and tubular-interstitial changes of 
various type which we will discuss in some detail in the following paragraphs.  
 
 
Table 2.  Main functional changes of the aging kidney (see text) 
 
Glomerular 
 ↓GFR 
Tubular 
 Impaired sodium balance 
 Impaired fluid balance 
 ↑ potassium retention 
 ↓ capacity to dilute urines 
 ↓ capacity to lower urine pH 
Vascular 
 ↓ ERPF (mostly in the cortex; conserved in the medullary) 
 ↓ capacity to lower urine pH 
 ↑ filtration fraction 
 ↑ post-glomerular RVRs 
 impaired vasodilatory responses 
Endocrine 
 ↓ plasma RA and aldosterone 
 ↑ EPO (in the healthy elderly) 
 ↓ EPO response to anemia 
 ↓ Vit-D activation 
 
EPO: erythropoietin; ERPF: effective renal plasma flow; GFR: glomerular filtration rate; RA: renin activity; 
RVRs: reno-vascular resistances. 
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Figure 4. Renal size (%) by age among 360 healthy adults. The size of the right kidney in the group aged 20-
29 was considered as reference value. Redrawn from (155). 
 
 
 
5.1 Glomerular changes 
The number of glomeruli in the adult kidney ranges from 330000 to 1100000 (159).  
Race, gender and birth weight are the main determinants of glomerulogenesis. The 
number of functioning glomeruli decreases during life-time (159, 160) while the 
proportion of hyaline and sclerotic glomeruli increases (13, 161-163) (Figure 5). 
Glomerular obsolescence goes along with intrarenal arterial changes, particularly with 
intimal fibroplasia (151). In very old living kidney donors, the prevalence of 
glomerulosclerosis, which can be as high as 70% (13), can be predicted by the formula: 
(age/2)-10 (164). Sclerotic glomeruli prevail in the subcapsular cortical zone in the 
elderly (165) and glomerulosclerosis purely attributable to aging is a multifactorial 
process which should be suspected when the renal interstitium shows scarce infiltration 
in the absence of changes characteristically seen in hypertensive and diabetic patients. 
Human podocytes are unable to undergo cell division and the number of these cells 
decreases with age (166, 167). In aged rats, podocytes undergo hypertrophy which 
eventuates in apoptosis, podocytopenia and glomerulosclerosis (168, 169). Brenner 
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hypothesis of renal aging holds that an altered control of glomerular hemodynamics 
increases glomerular plasma flow and intra-capillary pressure, leading to 
glomerulosclerosis (170, 171). Glomeruli spared from this process are hyper-perfused 
and hypertrophic and these functional adaptations may serve to maintain global 
glomerular filtration rate (172-175). However, this process becomes “maladaptive” in 
the long term, because glomerular hyperperfusion goes along with glomerular 
hypertension (170). Low glomerular density is a powerful predictor of renal function 
decline in patients with glomerulonephritides (176, 177). In elderly donors glomerular 
density is related in an inverse fashion to the proportion of sclerotic glomeruli (178). 
Glomerular basement membrane thickening is another typical feature of the aging 
glomeruli (179) as it is mesangial expansion (180). Direct shunts between afferent and 
efferent arterioles bypassing the glomerulal tuft in iuxta-medullary nephrons is an 
additional anatomo-pathological alteration commonly seen in kidneys of elderly 
subjects (180, 181).  
 
Figure 5. Sclerosis scores by age group among 1.203 living kidney donors defined as: (1) any global 
glomerulosclerosis, (2) any tubular atrophy, (3) interstitial fibrosis >5% and (4) any arteriosclerosis. In the 
figure a score of 0 is azure, a score of 4 is deep blue and intermediate scores are on a blue scale. Redrawn 
from (13). 
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5.2 Tubulo-interstitial changes 
The age-dependent decline in renal size and renal mass rests more on tubulo-interstitial 
changes than on glomerular or vascular changes (182, 183) and the same holds true for 
renal function (183). As described for glomeruli, the overall number of tubules 
decreases with age (184). Tubular length and volume are also markedly reduced and 
sparse areas of scarring, tubular atrophy and tubular diverticula are common in kidneys 
of elderly individuals (163, 185, 186). Tubular diverticula localize mainly in the distal 
convolute tubule and in the collecting duct and may give rise to form simple renal cysts 
(187), an alteration observed in about a half of subjects ≥40 years (188). Tubular 
dilatation may be accompanied by accumulation of hyaline material and basement 
membrane thickening. When extended, this process may lead to a sort of 
“thyroidization” of the kidney, a common feature in end-stage kidney disease. 
Wrinkling and thickening of basement membrane and simplification of the tubular 
epithelium is frequently observed in old kidneys, while the so called “endocrine” 
transformation with thin basement membranes and numerous mitochondria is a 
relatively rare involution pattern (184). Expanded interstitial volume, infiltration of 
mononuclear cells and diffuse areas of fibrosis are all hallmarks of the aging kidney (56). 
Excessive collagen deposition and structural changes in extracellular matrix, altered 
regulation of the expression of metalloproteinases and TGF-β, activation of fibrosis- and 
hypoxia-related genes all concur to the pathogenesis of tubulo-interstitial fibrosis in 
aging kidneys (189-192). Alterations in tubular function go along with anatomical 
involvement. Enhanced proximal sodium reabsorption coupled to reduced distal 
fractional reabsorption allows maintenance of a normal sodium balance under steady-
state conditions in the elderly (29). However, this functional resetting limits the ability 
to conserve sodium in response to low salt intake and makes elderly people 
predisposed to volume depletion and acute kidney injury (193). Inadequate activation 
of the renin-angiotensin system and reduced aldosterone secretion (hyporeninemic 
hypoaldosteronism) play a leading role into this phenomenon (194) as well as in 
nocturnal natriuresis, another frequent alteration in old people (195, 196). On the other 
hand, aged individuals display also a relative inability to excrete sodium excess in 
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response to salt load, a multifactorial alteration predisposing to salt retention, 
hypertension and cardiovascular congestion. Resistance to the natriuretic effect of 
atrial natriuretic peptide is a key step into this process (142). Alterations in tubular 
handling of electrolytes extend to potassium. Due to tubular atrophy and tubular-
interstitial scarring, Na-K ATPase activity is reduced in the elderly, resulting in a high risk 
for hyperkalemia. Reduction in GFR, hyporeninemic-hypoaldosteronism, dehydration, 
metabolic acidosis, all enhance the tendency to hyperkalemia in the elderly and the 
administration of potassium-sparing drugs may precipitate serious clinical events in 
individuals harboring these risk factors (197). The capacity of diluting and concentrating 
urine decreases with age in humans (198, 199). Reduced expression of urea 
transporters in the inner medullary collecting ducts impairs the capacity of 
appropriately raising urine concentration in aged rats (200) which also show a down-
regulation of vasopressin-2 receptors in the collecting duct and a reduced expression 
of the water-channels aquaporin 2 and 3 (201-203). Nocturia, which is in part a 
consequence of a reduced concentrating ability, is a typical feature of old age (198, 
204). On the other hand, elderly people exhibit also impaired urine diluting capacity 
which expose them to an increased risk of hyponatremia after water load (205, 206). 
Even though the renal regulation of acid-base balance is globally conserved in the aging 
kidney (207), the capacity of generating ammonia is clearly impaired (208). Elderly 
subjects are more prone than young individuals to develop acidosis in response to acid 
load (such as after a high-protein meal or in stress conditions which activate proteolysis) 
mainly because of the incapacity to increase ammonia and H+ synthesis (209-211).  
Impaired proton pump activity in the cortical collecting duct is a critical element in the 
deranged response to acid load in the elderly (208, 212). Renal-dependent metabolic 
acidosis has been implicated in a constellation of alterations in the elderly including 
hypercalciuria, decreased citrate excretion, enhanced protein catabolism, muscle 
wasting, bone dissolution, cardiomyopathy and progression of CKD (213). 
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5.3 Vascular changes 
Structural changes in renal vasculature are similar to those observed in vessels in other 
organ systems and include intimal and medial hypertrophy, arteriolosclerosis and overt 
atherosclerotic lesions (214). Post-mortem angiograms and histology studies show 
increased irregularity and tortuosity of pre-glomerular vessels, direct shunts between 
afferent and efferent vessels (see above), wall thickening and narrowing of the vascular 
lumen of afferent arterioles (215, 216), an alteration mainly depending on vascular 
smooth muscle cells proliferation (154). In addition, micro-infarctions triggered by 
cholesterol emboli are often observed along with atherosclerosis of the aorta and renal 
arteries in elderly patients with diabetes and hypertension. Interlobular arteries in the 
elderly show fibro-intimal hyperplasia (214), a feature typically observed in patients 
with chronic hypertension regardless of age.  
From adulthood to the age of 80 years, renal plasma flow (RPF) (15) and effective RPF 
(ERPF) exhibits a steady decline (29). Reduction in RPF mainly occurs in the renal cortex 
while medullary flow is relatively well preserved (214). Accordingly, the contribution of 
iuxtamedullary glomeruli to global GFR increases (29). Due to an increase in post-
glomerular renovascular resistances (RVR), the GFR is relatively better preserved than 
ERPF both in healthy elderly people and in elderly subjects with hypertension, heart 
failure and other cardiovascular co-morbidities (29). Reduced ERPF has obvious causal 
links with structural changes in the renal vasculature, particularly at post-glomerular 
level (181). Furthermore, the reno-vascular response to vasodilatory agents (217) and 
the sensitivity of renal arterioles to endogenous and exogenous vasoactive substances 
(103, 218, 219) is overtly altered in the elderly.  
 
5.4 Endocrine changes 
5.4.1 Renal Autacoids 
Autacoids, including prostaglandins, prostacyclins, thromboxanes and leukotrienes, are 
powerful endogenous vasoactive agents which also modulate platelet aggregation. The 
synthesis and the associated signaling transduction pathways of these complounds are 
altered by the aging process (220). Young and old rats fed at normal or low-salt diet, 
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have comparable levels of PGE2 and PGF2-α in the renal interstitial fluid (221). 
However, PGF2-α production is reduced and PGE2 enhanced in old rats as compared to 
young rats after sodium overload (221). In human studies, PGF1-α production is age-
dependent while the synthesis of other prostaglandins (such as PGE2 and PGF2-α) is in 
large part preserved in kidneys of elderly individuals (222). A defect in prostaglandin 
modulation has been postulated to explain the altered adaptive capacity of the aging 
kidney to respond to sympathetic stimulation, such as that by mental stress (223), 
particularly in elderly persons with isolated systolic hypertension (224). On the other 
hand, the inhibition of prostaglandin synthesis produces similar functional 
derangements in healthy elderly and young subjects (225). 
 
5.4.2 RAS system 
Plasma renin activity (226, 227) and aldosterone (228) are about halved in elderly 
subjects, a phenomenon mainly due to limited synthesis and release of renin, 
particularly under stress conditions (229). As alluded to before, reduced activation of 
the renin-aldosterone system (RAS) contributes to the development of various fluid and 
electrolyte abnormalities and partly accounts for the higher risk of dehydration, 
hypernatremia and hyperkalaemia which characterize elderly persons.  
 
5.4.3 Erythropoietin 
Circulating levels of erythropoietin (EPO) are higher in the healthy elderly as compared 
to younger individuals (230). Increased EPO production in the elderly is interpreted as 
a counter regulatory mechanism aimed at preserving normal red blood cells mass in 
response to a higher turnover, as well as to EPO resistance. However, EPO levels are 
reduced in anemic elderly individuals, suggesting an impaired counter-regulatory 
response to low hemoglobin levels (231). In a secondary analysis of the InCHIANTI 
study, old age went along with reduced EPO levels, anemia and impaired renal function 
(232).  
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5.4.4 Vitamin D 
Elderly people may develop vitamin D deficiency due to the impaired capacity of the 
aging kidney to convert 25-hydroxy vitamin-D to 1,25 dihydroxy vitamin-D (233) but 
extra-renal factors, i.e. 25-OH-vitamin D availability, affect at least equally vitamin-D 
sufficiency in the elderly. In a cohort study in 168 elderly patients with various degree 
of renal impairment, reduced 25-OH-vitamin D levels were independent predictors of 
progression to dialysis and death in the long term (234). In a secondary analysis of the 
BELFRAIL study, in individuals>80 years with conserved renal function higher 25-OH-
vitamin D levels associated with exposure to sunshine and with an active lifestyle (235) 
but not with renal function. CKD may worsen vitamin D deficiency in the elderly. Indeed, 
in post-menopausal women, the presence of CKD predicts the risk for bone fractures 
while calcitriol supplements reduce the incidence of falls, a protective effect which may 
depend on improved muscle strength promoted by up-regulation of vitamin D 
receptors (236). 
 
6.FUTURE PERSPECTIVES FOR RETARDING RENAL AGING 
As briefly alluded to before, dietary interventions to retard systemic and kidney aging 
have been extensively studied in animal models. Isocaloric diets with low-AGE content 
reduce kidney and cardiovascular damage associated with age and extend lifespan in 
rat models (237). Furthermore, powerful anti-oxidants, such as the methylglyoxal, 
potentiate the protective effects of low-AGE diets (238). A diet enriched of antioxidants 
(such as vitamin-E), reduces kidney lipid peroxidation and accumulation of F2 
isoprostanes and increases markedly the GFR (by 50%) in aging kidneys (95). Long-term 
administration of the NO precursor and ADMA antagonist L–arginine in aging rats 
ameliorates proteinuria and renal function (239). It was hypothesized that the 
beneficial effects of the “Mediterranean” diet on general health and lifespan might 
depend on the very low content in AGEs and on the high content of anti-oxidants of this 
diet (240). Caloric restriction retards age-related structural changes in the kidney, 
including glomerulosclerosis, ischemic injury, vascular wall thickening and tubular-
interstitial fibrosis (241). These beneficial effects associate with reduced expression of 
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the matrix-metalloproteinase-7, kidney injury molecule-1 and claudin-7 (242), as well 
as with a reduction in renal lipid accumulation (243), ceruloplasmin production (114) 
and apoptosis (130). In animal models of aging, such as the 24-months F344BN old rat, 
caloric restriction reduces aging-related proteinuria and extracellular matrix 
accumulation and these effects are apparently mediated by reduced expression of 
vascular endothelial growth factor (VEGF), plasminogen activator inhibitor (PAI)-1 and 
other connective tissue growth factors (244). Caloric restriction also preserves renal 
SIRT-1 expression, a sensor of redox and energy state with antiapoptotic and 
antifibrotic effects which is considered as a main factor in the cytoprotective 
mechanisms which may retard kidney aging (see above). No studies documenting a 
beneficial effect of long-term, low-calories diets on renal function exist in humans. 
However, long term caloric restriction ameliorates hypertension and the metabolic 
profile and retards atherosclerosis (245) and the decline in diastolic function in humans 
(246). Observations in the Nurses' Health Study (247) would support the contention 
that low protein intake may limit age-related decline in renal function in humans. 
Indeed, in a subgroup of women with normal renal function, the estimated change in 
GFR attributable to excessive protein intake was 0.25 mL/min/1.73 m2 per 10-g increase 
in protein intake over a 11-year period. Salt intake is another important modifiable 
factor which may retard renal function decline, mainly because low salt diets improve 
blood pressure control (248). In a small cohort of elderly hypertensive patients, the 
average salt excretion and the baseline eGFR were the only independent predictors of 
renal function decline (249). However, the observational nature of findings reporting a 
protective effect of low protein and sodium diets prevents causal interpretations and 
no recommendation for public health and clinical practice can be made on the basis of 
these data. Few drugs have been tested so far for retarding renal aging. In experimental 
studies, PPAR-γ agonists limit parenchimal sclerosis, alleviate cell senescence and 
improve GFR and proteinuria (250, 251). Increased renal expression of Klotho and 
reduced oxidative stress have been proposed as potential mechanisms to explain 
improvements by PPAR-γ agonists. Chronic treatment with angiotensin-converter 
enzyme inhibitors (ACEi) or ATR-blockers (ARBs) reduces age-related 
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glomerulosclerosis, mesangial expansion, tubular-interstitial fibrosis and mononuclear 
cells infiltration along with renal mitochondria damage (252). Furthermore, selective 
ATR-1 blockade prevents renal damage by increasing NO bioavailability and by reducing 
oxidative stress in aged spontaneous hypertensive rats (253). 
 
7.CONCLUSIONS 
Aging has been defined as “the collection of changes that render human beings 
progressively more likely to die” (254). This view implies the existence of an inexorable 
functional decline in biological systems in the whole organism. Whether aging is a 
disease or as the inevitable consequence of being human is a philosophical and a 
scientific question. Renal aging is a complex multifactorial process and ascertaining to 
what extent renal lesions in the elderly represent the life course exposure to chronic 
diseases or the local manifestation of systemic aging is tantalizing. Progress in genetics 
and proteomics provide promising new insights on renal aging. Proper lifestyle 
modifications, as those applicable to the general population, including the adoption of 
low-calories and low-AGEs diets with high content in anti-oxidants currently represent 
the most plausible approach to maintain kidney health. 
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ABSTRACT 
Renal patients are notoriously at high risk for cardiovascular complications but such risk 
is not fully explained by traditional and Chronic kidney disease (CKD)-related risk 
factors. New prognostic biomarkers are therefore needed to refine outcome prediction 
in this population. High pulmonary pressure (PP- also known as pulmonary 
hypertension) is remarkably prevalent among persons with CKD, particularly in 
hemodialysis patients. High PP is a powerful and independent predictor of death in the 
general population and in subjects with heart or lung diseases. In renal patients, there 
is now evidence showing that PP may hold the same prognostic utility. High PP predicts 
adverse cardiovascular outcomes in dialysis and pre-dialysis populations. In kidney 
transplant recipients, high PP is associated with worse renal outcomes. In this chapter, 
we will focus on high PP in the CKD population, spanning from the main techniques for 
assessing PP to the pathophysiology of pulmonary hypertension (PH) in renal patients. 
Prognostic implications of PH in CKD patients for risk stratification and therapeutic 
management will also be discussed. 
 
Keywords : pulmonary pressure, pulmonary hypertension, chronic kidney disease, end-
stage kidney disease, dialysis, cardiovascular risk 
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1. INTRODUCTION 
The incidence of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) is 
on the rise. Currently, it has been estimated that over 50 million people are affected by 
CKD and over 2 million persons need chronic dialysis for ESKD (1). This amount is 
expected to increase by 60% by 2020 (2). CKD ranks now as one of the main risk factors 
for cardiovascular (CV) mortality and morbidity with a substantial impact on health 
resources. In the US, annual costs attributable to manage CV complications of CKD 
patients rank from 1700 (KDOQI CKD-stage 1) to 12700 (CKD- stage 4) dollars (3). 
Although a large percentage of patients with CKD have traditional CV risk factors such 
as diabetes, hypertension and lipid abnormalities, interventions targeting these factors 
have failed to significantly decrease CV mortality and morbidity. Similarly, 
normalization of other non-traditional risk factors peculiar of CKD including anaemia, 
microalbuminuria, inflammation, oxidative stress and altered mineral metabolism, was 
not totally effective in improving event-free survival.  
High pulmonary pressure (PP) has recently emerged as a novel CV risk factor in the 
general population. In a surveillance from 1980 to 2002 (4), the Centers for Disease 
Control and Prevention identified increasing rates of hospitalization associated with 
high PP and stable death rates ranging from 5.2 to 5.4 per 100.000 persons. Conversely, 
during the last decade, an increasing trend in mortality was documented with an 
estimated age-adjusted death rate of 4.5 to 12.3 per 100.000 (5). High PP rarely 
presents as an idiopathic condition, being more frequently associated with systemic, 
cardiac or lung disorders which may affect the pulmonary vascular circuit.  
There is now accruing evidence indicating that masked, non-symptomatic high PP is 
exceedingly prevalent in CKD persons, particularly in ESKD patients on chronic renal 
replacement therapy (6). Several underlying conditions, such as volume overload, the 
presence of high-flow artero-venous fistulas, breath disorders and sympathetic hyper- 
activation have been postulated to explain such a high frequency. Nevertheless, PP is 
emerging as a novel, important prognostic biomarker in the renal population. In fact, 
the presence of high PP in CKD is generally associated with poor outcomes, spanning 
from increased mortality to higher rate of CV events and delayed graft function in renal 
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transplanted patients (6). The evaluation of PP might therefore represent an additional, 
helpful tool for risk assessment and risk stratification of renal patients. 
 
2. PULMONARY CIRCULATION AND PULMONARY PRESSURE ASSESSMENT 
Less known to nephrologists, who are more familiar with the systemic circulation, the 
pulmonary circulation is a delicate and exclusive low-resistance, low-impedance, high-
capacitance and high-flow circuit. Under physiological conditions pressure levels in the 
pulmonary arteries are roughly one fourth to one sixth of those normally found in the 
systemic circulation (7). Medial thickening of the major pulmonary arteries is notably 
lower than that of systemic arteries, being more similar to the structure of large veins. 
The normal pulmonary circulation therefore consists of highly compliant pulmonary 
arteries and a vast capillary network with large recruitment capability which is able to 
accommodate large increases in blood flow without significant increases in PP, e.g. 
during sustained exercise or in the presence of left-to-right congenital intra-cardiac 
shunts. How can PP be assessed in clinical practice? The gold standard of measurement 
is represented by right heart catheterization (RHC), an invasive procedure which 
consists in reaching the right heart with a catheter inserted via a peripheral vein (8). 
The catheter can be moved until the right atrium or even further, reaching the right 
ventricle and the main pulmonary artery branches. As long as the catheter proceeds 
through the right heart to the pulmonary circulation this gets characteristic pressure 
responses, very similar to a sequence of spikes, peaking at about 20-25 mmHg. When 
in the distal branch of the pulmonary artery, values of the measured PP of about 14 +/-
3 mmHg are considered as normal. The assessment of the so-called pulmonary artery 
wedge pressure (PAWP), that is the pressure measured by wedging a Swan-Ganz 
catheter with an inflated balloon into a small pulmonary arterial branch, may give 
additional information, particularly in the presence of pathological PP values (see 
below). In fact, PAWP allows to assess the pulmonary vascular resistance (PVR), 
expressed as the ratio between the difference of mean PP and PAWP and the cardiac 
output. RHC is crucial for assessing PP but as it is an invasive procedure it may be 
associated with an increased risk of dangerous complications. Therefore, with some 
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exceptions, cardiac catheterization in daily practice is usually not considered as the first 
line approach to evaluate PP.  In most cases, PP is firstly estimated by non-invasive 
procedures, like a simple transthoracic Doppler echocardiography. PP estimation with 
such technique is based on the eventual finding of tricuspidal regurgitation, a 
phenomenon that can be minimally present also in apparently healthy subjects. If 
tricuspidal regurgitation is present, the echocardiography instrument can automatically 
assess the Vmax, that is the maximum tricuspidal jet velocity. This parameter is 
important to finally estimate the PP (ePP) according to the so-called Bernoulli’s 
equation as the product of the square of the Vmax by 4 (4x Vmax2) (9). However, this 
equation often gives a too much rough estimate of ePP that can be further refined by 
implementing also information about the estimated right atrial pressure (RAP) in the 
“modified” Bernoulli’s equation (4x Vmax2+ RAP) (10). RAP is supposed to range from 
10 to 30 mmHg in case of absence or presence of relevant inferior vena cava collapse.  
 
3. DIAGNOSING HIGH PP 
A recent joint guideline (11) made by the European Society of Cardiology (ESC) and the 
European Respiratory Society (ERS) has established the main criteria for the definition 
of “pathological” PP values, finally making clearness in a very controversial and debated 
topic. High, pathological PP (a condition also known as Pulmonary Hypertension-PH) is 
defined by a documented increase in the measured PP (mPP)≥25 mmHg at rest. 
However, although not diagnostic, ePP values 35-49 mmHg (roughly corresponding to 
Vmax values of 2.8-3.4 m/s) can be considered suggestive of PH while values ≥50 mmHg 
are strongly indicative of the true presence of PH. Echocardiography estimation can 
then be useful as screening test for selecting patients who deserve more invasive exams 
for a clear-cut diagnosis of pathological PP. Even though is of foremost importance to 
be sure about the true diagnosis/presence of pathological PP, it is also important to 
identify the underlying cause of such alteration. As briefly alluded to before, mPP or 
ePP values alone are not sufficient to make a differential diagnosis of PH and additional 
parameters, such as PAWP and PVR, are required.  According to the ESC-ERS guideline, 
which has recently been endorsed by a WHO document, different types of PH exist, 
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each one with its peculiar natural history and clinical approach. The WHO classification 
(12) of the different types of PH mostly looks at the pathogenesis and the anatomic 
location of the primary alteration responsible of increased PP (Figure 1). As mentioned, 
the pulmonary circulation consists of an arterial side that mostly recall the 
characteristics of systemic veins in terms of compliance and sectional structure and a 
venous side bringing the oxygenated blood back to the heart and, from there, to the 
systemic circulation. The capillary barrier, that is ideally in the middle between the two 
sides, can be useful to distinguish pathological conditions characterized by a primary 
increase in pulmonary artery resistances, the so-called “pre-capillary” pulmonary 
hypertension, from those mostly secondary to a passive venous congestion (“post-
capillary”). PAWP and PVR can be helpful in discriminating pre-capillary from post-
capillary forms of high PP. In pre-capillary forms, PAWP is low (<15 mmHg) while PVR 
are expectedly high (> 3 Woods units); conversely, in post-capillary forms PAWP values 
are increased (>15 mmHg) with usually low PVR (<3 Woods units) (8). Pre-capillary 
forms of PH include the so-called “Pulmonary arterial hypertension” (PAH) which 
encompasses idiopathic (IPAH), familial (FPAH) or forms associated (APAH) to 
congenital heart disease, connective tissue diseases, drugs and toxins, HIV infection, 
portal hypertension or pulmonary veno-occlusive disease. In addition, pre-capillary PH 
can arise as consequence of chronic thromboembolism such as in the presence of 
obstruction of pulmonary arterial vessels (proximal or distal) by thromboemboli, 
tumors, or foreign bodies. Post-capillary forms are most frequently found as associated 
to left heart disorders such as systolic or diastolic dysfunction or valve diseases (mitral 
and/or aortic). High PP can be found also in the presence of other conditions primarily 
affecting the lungs (e.g. chronic obstructive pulmonary disease (COPD), interstitial lung 
disease (ILD), sleep apnea) or as manifestation of several systemic diseases (12). These 
two latter cases can present either with a prevalent pre-capillary or post-capillary 
involvement so that a proper differential diagnosis based on PAWP and PVR is not 
always possible. Figure 2 depicts a diagnostic algorithm that can be useful for 
approaching patients with suspected pathological PP. As said, the first approach would 
be to perform a non-invasive assessment of PP by echocardiography. ePP of 35-49 
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mmHg or Vmax 2.8-3.4 m/s are suggestive of PH but would require RHC for the final 
diagnosis. ePP>50 mmHg or Vmax> 3.4 m/s might be considered diagnostic of PH, but 
RHC is needed for further characterization of PH (pre- or post-capillary) on the basis of 
PAWP and PVR values. 
 
 
Figure 1. Differential diagnosis of high pulmonary pressure in relation to the anatomic site of disease 
 
COPD: chronic obstructive pulmonary disease; ILS: interstitial lung syndrome; PAWP: pulmonary artery wedge 
pressure; PP: pulmonary pressure; PVR: pulmonary vascular resistance 
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Figure 2. Diagnostic algorithm for approaching patients with suspected high pulmonary pressure 
 
mPP: measured pulmonary pressure; PAWP: pulmonary artery wedge pressure; PP: pulmonary pressure; 
PVR: pulmonary vascular resistance; RHC: right heart catheterization  
 
4. SIGNIFICANCE OF HIGH PP IN THE GENERAL POPULATION AND IN RENAL PATIENTS 
What is the epidemiological impact of elevated PP? In other words, what do studies and 
registries report about the penetrance and diffusion of this condition? Recently, 
evidence is accruing showing that high PP is much more prevalent in the general 
population than expected (13). This condition might remain undetected because of the 
absence of symptoms in the early phases and suspected only when clinical signs of right 
ventricular dysfunction (dyspnea, fatigue, non-productive cough, angina pectoris, 
syncope, peripheral edema and, rarely, hemoptysis) are manifested (8). In the Olmsted 
county study (14), a general population study conducted in a random sample of the 
same county, the prevalence of high PP defined by a Doppler-derived PP>35 mmHg was 
about 5% in individuals older than 45 years. Most cases of high PP detected in this 
population were secondary to concomitant left heart disorders and the presence of 
high PP was predicted by diastolic dysfunction as measured by the E/e’ (early trans-
mitral flow velocity [E] to early mitral annular tissue velocity [e’]) ratio and by the 
presence of systemic hypertension and high pulse pressure. In a survey on 4579 
patients undergoing echocardiographic examinations (15), the prevalence of high PP 
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(>40 mmHg) was 10.5%. Among the 483 cases with elevated PP 78.7% had left heart 
disease, 9.7% had lung diseases, 4.2% had primary pulmonary artery hypertension and 
0.6% had pulmonary thromboembolism. In another study (16), the prevalence of PH in 
patients with chronic heart failure increased with the progression of NYHA class. Up to 
60% of patients with severe LV systolic dysfunction and up to 70% of patients with 
isolated LV diastolic dysfunction had pathologically high PP. Pre-capillary forms of PH 
are less frequent with an annual incidence of about 2-3 per million and an estimated 
prevalence of about 15 cases per million (13). Adult females are almost three times 
more likely to present with PAH than males. In children, the presence of PAH is equally 
split along gender lines. But what happens if we refer specifically to renal patients? Do 
things change in this particular population? Although epidemiological data are scarce 
and sparse and mainly based on retrospective studies, high PP appears to be 
exceedingly prevalent among renal patients and not only confined to connective tissue 
and systemic diseases (Figure 3). Among pre-dialysis patients, the prevalence of PH is 
about 2 to 8 times higher than in the general population, ranging from 9% to 39% (6). 
PH prevalence is higher in the dialysis population (CKD-5D) than in CKD-ND patients. 
With regard to dialysis modality, the prevalence of PH is lower in patients on peritoneal 
dialysis (from 0% to 42%) than in hemodialysis patients (from 18.8% to 68.8%) (6). 
Unfortunately, there is a lack of uniformity among studies with respect to the ePP cut-
offs considered as “pathologic” (ranging from 25 to ≥45 mmHg). Such a variability in the 
diagnostic criteria explains the wide range of PH prevalence reported in CKD patients 
and hampers the possibility to perform rough comparisons between studies and to 
provide reliable overall estimates of the frequency of high PP among renal patients.  
But what kind of PH do renal patients have? Understanding the type of PH would be 
useful to better understand the pathophysiology of this condition and, eventually, to 
plan also the best treatment in such patients. Unfortunately, as stressed before, the 
only way to characterize the nature/origin of high PP is to perform RHC to measure PP 
but also to assess PAWP and PVR. In the only study measuring PP by RHC (17), PH was 
present in 81% of HD and 71% of pre-dialysis patients. The prevalence of (pre-capillary) 
high PP was 6% in CKD stage 4-5 patients and 13% in HD patients and the prevalence of 
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post-capillary PH was 71% and 65% respectively. These observations, although partly 
biased by the strict inclusion criteria of the study population (all subjects underwent 
RHC for characterization of an unexplained dyspnea after exclusion of other potential 
causes), seem to indicate that high PP is mostly post-capillary also in the renal 
population.  
 
Figure 3. Reported prevalence of high estimated pulmonary pressure (ePP) in renal patients. Each dot 
represent a single prevalence reported in a different study cohort (see text). Grey dots indicate prevalence 
of high ePP in CKD stage 1-4 populations; blue dots in CKD stage-5 not on dialysis; purple dots in CKD stage-5 
on chronic hemodialysis treatment; azure dots in CKD stage-5 on chronic peritoneal dialysis treatment. 
Correspondent lines indicate the median (calculated) value of high ePP prevalence in a given CKD class. 
 
ePP: estimated pulmonary pressure; CKD 1-4: chronic kidney disease stage 1-4; CKD 5ND: chronic kidney 
disease stage 5 not on dialysis; CKD 5D: chronic kidney disease stage 5 on dialysis; GP: general population 
 
 
 
_____________________Pulmonary pressure as a novel prognostic biomarker in renal patients 
 
71 
 
5. RISK FACTORS OF HIGH PP IN RENAL PATIENTS 
As alluded to before, post-capillary high PP is likely to depend on the presence of LV 
disorders. Heart dysfunction is prevalent in the renal population, particularly in chronic 
hemodialysis patients. This condition can trigger volume overload but can be 
aggravated itself by fluid excess, therefore generating a vicious circle that can 
contribute to pulmonary congestion and high PP. Nevertheless, other risk 
factors/conditions may trigger and/or exacerbate PH in renal patients (Figure 4). 
Artero-venous fistula (AVF) is known to induce a decrease in systemic vascular 
resistances, which increases venous return and cardiac output to maintain proper blood 
flow to peripheral tissues. These hemodynamic effects might increase pulmonary blood 
flow and set the stage for high PP. Accordingly, high PP are more prevalent among HD 
than PD patients or CKD patients not on dialysis; furthermore, PP rises in strict 
parallelism with AVF creation (18) and tends to worsen overtime in the HD population 
(19, 20). However, evidence that renal transplantation may revert to normal PP in 
patients who still have a functioning AVF (21) indicates that other risk factors are 
involved in the genesis of high PP in CKD. Endothelial dysfunction is a major 
determinant of PH in the general population (22) and is exceedingly frequent in renal 
patients (23). Plasma levels of the powerful, endothelial-derived, vasodilator nitric 
oxide (NO) are more reduced in HD patients with higher PP (24). Furthermore, 
Asymmetric dimethyl-arginine (ADMA), an endogenous inhibitor of NO synthase which 
is copiously synthesized at lung level (25), has been strongly involved in experimental 
(26) and in primary forms (27) of PH and accumulates in subjects with renal function 
impairment (28). Interestingly, ADMA is increased in patients with sleep breathing 
disorders (29). Sleep breathing disorders, particularly sleep apnea, are highly pervasive 
in both pre-dialysis (30) and dialysis patients (31) and nocturnal hypoxemia by sleep 
apnea, is a strong trigger of high PP by enhancing sympathetic activation (32, 33).  
Chronic exposure of blood to dialysis membranes causes reversible neutrophil 
sequestration in the lung and neutrophils activation (34) which may contribute to 
micro-vascular lung disease and PP increase in HD patients (35). The control of micro-
vascular tone in the lung might also be affected by other diseases, such as diabetes, 
Chapter 3______________________________________________________________________ 
72 
 
connective, liver, infectious and hematologic diseases. Severe anaemia is a recognized 
cardiovascular risk factor in renal patients and its impact on the cardiovascular system 
includes direct effects to the pulmonary circulation. Indeed, anaemia could worsen PH 
by aggravating hypoxia (36). As a consequence of the overall dysfunction in mineral 
metabolism, arterial rigidity is increased in renal patients and calcium deposits have 
been found even in the pulmonary artery of CKD patients (37). These findings are in line 
with observations in the general population showing that stiffening of the pulmonary 
artery is significantly correlated to high PP (14).  
 
Figure 4. Main pathophysiologic mechanisms leading to an increase in pulmonary pressure in renal patients 
 
ADMA: asymmetric dimethyl-arginine; AV-fistula: Artero-venous fistula; COPD: chronic obstructive 
pulmonary disease; LV: left ventricular ; NO: nitric oxide; PBF: pulmonary blood flow.  
 
6. POTENTIAL APPLICATIONS TO PROGNOSIS, OTHER DISEASES OR CONDITIONS 
What is the prognostic impact of high PP? Do we have to fear the presence of PH in CKD 
patients? A large US survey (4), which collected data on PH at the community level over 
a 22 year-period (1980-2002), documented a stable death rate in patients with 
pathologically high PP, ranging from 5.2 to 5.4 per 100.000. Conversely, over the last 
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ten years, an increasing trend in mortality was documented with an estimated age-
adjusted death rate of 4.5 to 12.3 per 100.000 (5). In addition, high PP was also 
associated with steadily increasing rates of hospitalizations (4). With this background in 
mind, one would easily argue that this trend simply reflects that one of “common” 
cardiovascular or pulmonary diseases; in this view, PH would be nothing more than a 
simple complication of traditional heart or lung disorders. However, a milestone study 
on PH in cardiopathic subjects has promptly rejected this hypothesis (38). The Authors 
studied over four hundred patients with known or presumed heart failure. After 
echocardiographic assessment of PP and LV ejection fraction patients were followed for 
up to 5.5 years. Patients presenting with a substantial increase in PP (>39 mmHg) had a 
significantly increased mortality in the long-term (5 years) and even in the short term 
(1 year) with respect to those with lower PP values. Interestingly, these observations 
remained unaffected if patients were stratified according to the presence of a 
conserved or impaired LV function (≤50% or > 50%). Multiple Cox analyses apportioned 
a 9% increase in mortality per each 5 mmHg increase in PP, independently of age and 
presence of chronic lung disease, heart failure and impaired renal function. These solid 
findings indicate that the prognostic impact of high PP is not influenced by traditional 
risk factors, including heart dysfunction. Similar observations have been extended to 
other populations, such as patients with primary PH or PH mostly secondary to chronic 
lung disease (39). What happens in renal patients? Do high PP hold the same prognostic 
power even in this particular, high risk population? A study in 2003 (40) tested for the 
first time this possibility in a cohort of chronic hemodialysis patients. Indeed, at 
unadjusted Kaplan-Meier survival curves, patients with ePP≥35 mmHg showed poorer 
survival with respect to those with lower ePP over a 5-year follow-up. These preliminary 
observations prompted the Authors to carry out an observational study (41) on a wider 
cohort of 127 ESKD patients initiating chronic renal replacement therapy. Patients’ 
survival was assessed over a longer follow-up period (7 years) and subjects were 
stratified according to the absence of PH (ePP<45 mmHg) or to the presence of 
prevalent PH (ePP>45 mmHg already present before starting HD treatment) or incident 
PH (ePP>45 mmHg developed after starting HD). Overall, the presence of high PP 
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conferred a higher risk of death (hazard ratio 2.1 and 3.6 for incident and prevalent PH, 
respectively) and patients already having abnormal PP values before starting dialysis 
had poorer survival as compared to those developing PH after dialysis initiation. 
Furthermore, the prognostic power of high PP was independent of gender, age at onset 
of HD and presence of diabetes mellitus, left ventricular dysfunction and clinically 
relevant valve disease. In this study each 10 mmHg increase in ePP was associated with 
a fully adjusted increased risk of mortality of 50%. Similar findings were reported in 
another cohort of 278 patients on chronic renal replacement therapy who were 
followed for 24 months (42). In this series, the prevalence of ePP>35 mmHg was as high 
as 35%. Subjects with baseline PH had a hazard ratio of cardiovascular death of 2.36 
with respect to those with “normal” ePP. This increased risk was fully independent of 
several potential confounders, such as gender, age at HD onset and duration of HD, pre-
dialysis diastolic blood pressure, serum phosphorus, urea levels, presence of diabetes, 
systolic dysfunction and history of CV events. Of note, the presence of high ePP was 
also a powerful predictor of non-fatal cardiovascular events (hazard ratio 2.27), even 
after adjustment for the above-mentioned risk factors plus medication with ACEi or 
ARB, dialysis adequacy and C-Reactive Protein. In another study of 288 chronic HD 
patients (43), high ePP (>35 mmHg) was found in 38% of subjects and its presence 
predicted by left atrial dysfunction, urea removal ratio and use of vitamin-D receptor 
activators. During follow-up (Median 2.15 years) patients with higher ePP had 
significantly worsen cumulative hazard estimates of cardiovascular fatal events (53%, 
crude mortality rate 168.9/1000 patient-years vs. 22%, crude mortality rate 52.5/1000 
patient-years). After adjustment for race, age, vascular access, serum albumin and 
history of CV disease, the presence of ePP>35 mmHg still conveyed a higher risk of 
death (hazard ratio 2.17) in this population. Another study (44) found abnormal ePP 
values (defined as Vmax>2.5 m/s) in 42/90 HD patients (47%). Subjects were followed 
over 12 months to assess all-cause mortality and hospitalizations. There was a 
statistically significant parallelism among severity of PH (defined as low: Vmax<2.5 m/s, 
mild: Vmax 2.6-2.9 m/s or severe: Vmax>3m/s) and mortality trend but no differences 
were found in all-cause hospitalizations. Recently, the prognostic impact of PP was 
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extended also to persons with early CKD (KDOQI stages 2-4) (45). In a series of 468 
subjects with early renal impairment, the estimated prevalence of PH according to an 
ePP cutoff of 35 mmHg was 23% and the presence of high ePP was predicted by age 
and left atrial volume. Patients were followed over time (median 4 years) to assess the 
incidence of a combined endpoint including cardiovascular death, acute 
decompensated heart failure, coronary artery disease events as well as cerebrovascular 
and peripheral artery events. In a Cox multivariate model adjusting for age, eGFR, 
haemoglobin, left atrial volume, left ventricular mass and presence of diabetes mellitus 
and background CV disease, high ePP predicted a high risk for the combined 
cardiovascular end-point (Hazard Ratio 1.75). Thus, PH is remarkably prevalent also in 
patients with non-advanced CKD and holds its prognostic capacity with respect to 
adverse CV outcomes independently of classical and CKD-specific risk factors. 
Accruing evidence is indicating that the prognostic utility of PP might be extended also 
to outcomes of kidney transplant recipients.  In a retrospective, 3-year observational 
study (46) 55 patients undergoing renal transplantation were studied with respect to 
the incidence of early graft dysfunction (EGD), defined either as delayed or slow graft 
function. The percentage of patients developing EGD was higher within the subgroup 
of patients with high ePP (>35 mmHg). Furthermore, this increased risk (odds ratio 15.0) 
was fully independent from other traditional risk factors such as age of recipient, history 
of coronary artery disease, left ventricular ejection fraction, pre-transplant HD, 
presence of functional AVF, age of donor and cold ischaemia time. Another 
retrospective study (47), analyzed the clinical course of 215 transplant candidates. The 
Authors stratified these subjects into three different ePP categories (<35mmHg; 35-59 
mmHg and >60mmHg). Despite most of them had ePP apparently falling within normal 
values, more than one third presented with frankly pathological values. Roughly 10% of 
the study cohort had even seriously high ePP (>60mmHg). The severity of ePP was 
directly correlated to dialysis vintage and the presence of a severe PH (ePP>50 mmHg) 
was a significant predictor of death after transplantation even after adjustment for age, 
reduced left ventricular ejection fraction, serum albumin and delayed graft function. 
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Table 1 summarizes the main findings from prognostic studies of high PP in renal 
patients. 
 
Table 1. Main prognostic studies of high PP in renal patients 
Studies looking at mortality and CV outcomes 
Study/year Country Population 
High ePP 
prevalence 
ePP 
Cutoff 
Follow-
up 
Results 
Yigla et al. 
2003 
 
Israel 58 HD 
5 PD 
39.7% HD 
0 % PD 
≥35 
mmHg 
>5-years At unadjusted 
Kaplan-Meier 
survival curves, 
patients with ePP≥35 
mmHg had poorer 
survival with respect 
to those with lower 
ePP 
Yigla et al. 
2009 
 
Israel  127 HD 29.1%  ≥45 
mmHg 
7-years High PP conferred a 
higher risk of death 
(HR 2.1 and 3.6 for 
incident and 
prevalent PH, 
respectively) with a 
fully adjusted HR of 
mortality of 1.5 (1.2–
1.9) for each 10 
mmHg increase in 
ePP; (p=0.0007) 
Li et al. 
2013 
China 278 HD 64.7% ≥30 
mmHg 
2-years Subjects with 
baseline high PP had 
a HR of CV death of 
2.36 with respect to 
those with normal 
ePP. High ePP was 
also an independent 
predictor of non-fatal 
CV events (HR 2.27) 
Agarwal 
2012 
US 288 HD 38% ≥35 
mmHg 
2.15-
years 
(median) 
The presence of 
ePP>35 mmHg 
conveyed a higher 
risk of death (HR 
2.17) after 
adjustment for race, 
age, vascular access, 
serum albumin and 
history of CV disease  
Ramasubbu 
et al. 2010 
US 90 HD 47% Vmax≥2.5 
m/s 
>1-year Statistically 
significant 
parallelism between 
severity of PH 
(defined as low: 
Vmax<2.5 m/s, mild: 
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Vmax 2.6-2.9 m/s or 
severe: Vmax>3m/s) 
and mortality trend 
but no differences in 
all-cause 
hospitalizations 
Bolignano 
et al. 2015 
Italy/ 
Germany 
468 CKD 23% ≥35 
mmHg 
4-years 
(median) 
In a Cox multivariate 
model adjusting for 
age, eGFR, 
haemoglobin, left 
atrial volume, LVM 
and presence of 
diabetes mellitus and 
background CV 
disease, high ePP 
predicted a high risk 
for a combined CV 
end-point (HR 1.75) 
Studies looking at renal outcomes in kidney transplant recipients 
Study/year Country Population 
High ePP 
prevalence 
ePP 
Cutoff 
Follow-
up 
Results 
Zlotnick et 
al.  2010 
 
US 55 HD 38% ≥35 
mmHg 
3-years Higher percentage of 
patients developing 
EGD within the 
subgroup with high 
ePP (>35 mmHg) 
with a fully adjusted 
OR of 15.0  
Issa et al. 
2008 
 
US 215 
CKD/HD/PD 
32% ≥35 
mmHg 
2.5-
years 
The presence of a 
severe PH (ePP>50 
mmHg) was a 
significant predictor 
of death after 
transplantation after 
adjustment for age, 
reduced left 
ventricular ejection 
fraction, serum 
albumin and delayed 
graft function 
 
CKD: chronic kidney disease; CV: cardiovascular; EGD: early graft dysfunction; eGFR: estimated glomerular 
filtration rate; ePP: estimated pulmonary pressure; HD: hemodialysis; HR: hazard ratio; LVM: left ventricular 
mass; OR: odds ratio; PD: peritoneal dialysis; PH: pulmonary hypertension; PP: pulmonary pressure; Vmax: 
maximum tricuspidal jet velocity 
 
Although few doubts exist on the prognostic usefulness of PP in this population, one 
question still remains open –that is: is pathologically high PP also as a modifiable factor 
that deserves correction? Unfortunately, to date there are no specific studies of PH 
Chapter 3______________________________________________________________________ 
78 
 
treatment in CKD patients. In the absence of such evidence one can refer to the 
therapeutic algorithm proposed by current guidelines on PH (11) (Figure 5). In the 
general population, the first step is basically to confirm the presence of high PP and to 
assess the severity and possible type of PH by right heart catheterization. The second 
step would be to tailor the best treatment to the patient according to the (invasive) 
vasoreactivity test and the individual response to drug. Nevertheless, given the peculiar 
characteristics of renal patients, is there any additional approach that could be 
particularly useful in the CKD setting? Of course, the ideal solution would be to 
encourage kidney transplantation since accumulating (although not univocal) evidence 
indicates that PP may revert to normal values after receiving a renal transplant. Yet, as 
briefly alluded to before, a higher risk of death may persist in kidney transplant 
recipients with previous PH even after normalization of PP (47). Volume overload 
correction by ultrafiltration intensification or peritoneal dialysis might improve LV 
dysfunction and sleep apnea. The identification and surgical treatment of very high flow 
AVF would probably be helpful as well. Finally, when a pharmacological approach is 
needed, this should be always weighted on a risk/benefits balance, considering that 
most drugs for PH treatment can be dangerous in patients with impaired renal function 
or on dialysis. 
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Figure 5. Potential therapeutic approach to high pulmonary pressure in renal patients 
 
AVFs: artero-venous fistulas; CCBs: calcium-channel blockers; ERAs: endothelin-receptor antagonists; HD: 
hemodialysis; IV: intravenous; LV: left-ventricular; PDE-5 Is: phosphodiesterase-5 inhibitors; PD: peritoneal 
dialysis; PH: pulmonary hypertension; SC: subcutaneous.  
 
7. CONCLUSIONS 
Evaluation of pulmonary pressure might represent an additional prognostic tool for risk 
stratification of renal patients. Pulmonary hypertension is highly prevalent in CKD 
patients, particularly in stage 5 patients on chronic HD. PH in CKD is a potentially 
reversible process because it may regress after kidney transplantation. However, in 
dialysis patients with established PH the excess risk for death may persist after kidney 
transplantation. Accruing evidence indicates that high PP predicts a high risk of death, 
particularly in ESKD patients, and worse outcomes in kidney transplant recipients. Large 
prospective studies adopting well standardized criteria of PP measurement, such as 
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right heart catheterization, are needed to clarify the exact risk of PH in persons with 
CKD. 
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ABSTRACT 
High estimated pulmonary artery systolic pressure (ePASP) is an established risk factor 
for mortality and CV events in the general population. High ePASP predicts mortality in 
dialysis patients but such a relationship has not been tested in early CKD patients. In 
this study we estimated the prevalence and the risk factors of high ePASP in 468 
patients with CKD stage 2-4 and investigated its prognostic power for a combined 
endpoint including cardiovascular death, acute heart failure, coronary artery disease, 
cerebrovascular and peripheral artery events. High ePASP (≥35 mmHg) was present in 
23% (n=108) of CKD patients. In a multivariate logistic regression model adjusted for 
age, diabetes, hemoglobin, left atrial volume (LAV/BSA), left ventricular mass 
(LVM/BSA) and history of CV disease, age (OR 1.06; 95% CI 12 1.04-1.09; p<0.001) and 
LAV/BSA (OR 1.05; 95% CI 1.03-1.07; p<0.001) were the sole independent predictors of 
high ePASP. High ePASP predicted a high risk for the combined cardiovascular end-point 
both in unadjusted analyses (HR 2.70; 95% CI 1.68-4.32; p<0.001) and in analyses 
adjusting for age, eGFR, haemoglobin, LAV/BSA, LVM/BSA and presence of diabetes and 
CV disease (HR 1.75; 95% CI 1.05-2.91; p=0.03). High ePASP is exceedingly prevalent in 
patients with stage 2-4 CKD and predicts adverse CV outcomes independently of 
established classical and CKD-specific risk factors. The question whether high ePASP is 
a modifiable risk factor in CKD patients should be addressed in appropriate randomized 
clinical trials.  
 
Keywords: Pulmonary hypertension, chronic kidney disease, cardiovascular events, 
cardiovascular death.  
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1. INTRODUCTION 
Patients with chronic kidney disease (CKD) are notoriously at very high risk for 
cardiovascular events and premature death (1). Data extracted from extensive 
databases in Canada document that the death risk of subjects with a GFR <60 
ml/min/1.73 m² is of the same order of that in patients who had suffered a myocardial 
infarction and about twice higher than that in diabetic patients without CKD (2). Such a 
high risk derives from exposure to classical cardiovascular risk factors prior to CKD and 
thereafter to CKD-specific risk factors, encompassing anemia, protein wasting, 
inflammation and CKD-metabolic bone disorders (CKD-MBD) whose burden 
progressively increases as CKD evolves toward kidney failure (3). Left Ventricular 
Hypertrophy (LVH) and LV function disorders are highly prevalent in CKD and these 
alterations are considered as powerful integrators of the overall burden of classical and 
CKD-specific risk factors on the cardiovascular system in this population (4). However, 
even when considered in a context including simultaneous vascular disease, these 
disorders largely fail to explain in full the risk excess for cardiovascular events 
portended by CKD, indicating that other, hitherto overlooked, cardiovascular disorders 
play a role in the high risk for such events.  High pulmonary artery systolic pressure 
estimated by echocardiography (ePASP) is an emerging, novel CV risk factor in the 
general population (5) (6). This condition is exceedingly prevalent in asymptomatic 
dialysis patients (7). Several risk factors such as volume overload, the presence of high-
flow artero-venous fistulas, sleep apnea and sympathetic hyper-activation have been 
postulated to explain the high risk for elevated ePASP in these patients and some 
studies also documented that elevated ePASP predicts a high risk for all-cause and 
cardiovascular mortality in this population, as reviewed recently (7). ePASP evaluation 
in pre-dialysis CKD patients has received very scanty attention. Only one study has so 
far analyzed ePASP in early CKD stages (stage 1 to 3) (8) while studies looking at ePASP 
in advanced CKD included mainly CKD-stage 5 patients and just a small number of CKD-
stage 4 patients without providing separate data or targeted analyses (9, 10). In this 
study we therefore aimed to estimate the prevalence and prognostic implications of 
ePASP in a large cohort of stage 2-4 CKD patients gathered by combining two cohorts 
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in a department of Nephrology in Germany (the CARE FOR HOMe study cohort) and in 
a Renal Unit in Italy (the MAURO study cohort). 
 
2. METHODS 
2.1 Patients and Baseline Data  
Individual patient data were pooled from two inception cohorts with available 
echocardiography data of the MAURO study (n=80; Reggio Calabria, Italy) and from the 
CARE FOR HOMe study (n=388; Homburg, Germany). The patients flow diagram is 
depicted in Figure 1. Study cohorts, research protocols and main objectives of the 
MAURO and CARE FOR HOMe studies have extensively been described elsewhere (11, 
12). Briefly, the two cohorts had very similar main inclusion criteria including: CKD-
KDOQI stage 2 - 5 ND (MAURO) and CKD-KDOQI stage 2-4 (CARE FOR HOMe); age 18 - 
75 years (MAURO) and age > 18 years (CARE FOR HOMe). Both cohort excluded patients 
with acute kidney injury; transplant patients, pregnant women and patients with active 
cancer or systemic diseases in the terminal phase. Patient enrollment was performed 
between October 2005 and November 2007 (MAURO), and between September 2008 
and November 2012 (CARE FOR HOMe). The main demographic and clinical 
characteristics of the patients in the combined cohort are given in Table 1. The study 
protocol conformed to ethical guidelines and was approved by ethics committees of 
the nephrology units that participated. Written informed consent was obtained from 
each patient. 
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Figure 1. Study flow diagram  
 
 
Table 1. Demographic, somatometric and clinical data of the study population 
 
  
Whole 
Cohort 
(N=468) 
ePASP<35 
mmHg 
(N=360;77%) 
ePASP≥35 
mmHg 
(N=108;23%) 
p 
Age (years) 64±12 62±13 71±9 <0.001 
Male sex n. (%) 280 (60) 212 (59) 68 (63) 0.50 
BMI (kg/m2) 29±5 29.6±5.2 29.1±4.88 0.40 
Systolic blood pressure (mmHg) 149±24 149±24 153±27 0.11 
Diastolic Blood Pressure (mmHg) 85±13 86±13 83±13 0.16 
Diabetes n. (%) 165 (35) 118 (33) 47 (43) 0.04 
Current smokers n. (%) 59 (13) 51 (14) 8(7) 0.06 
Total cholesterol (mg/dl) 190±42 191±42 184±42 0.13 
Haemoglobin (g/dl) 13.4±1.6 13.5±1.6 12.9±1.6 <0.001 
Albumin (g/dl) 4.4±0.4 4.4±0.4 4.7±0.4 0.87 
Serum phosphate (mg/dL) 3.4±0.7 3.4±0.7 3.5±0.8 0.17 
eGFR (mL/min/1.73m2) 45.2±17.6 46.3±17.7 41.5±16.9 0.01 
Albuminuria (g/g creat) 
0.04 (0.007-
0.21) 
0.04 (0.006-
0.22) 
0.04 (0.009-
0.21) 
0.94 
ePASP (mmHg) 10 (10-34) 10 (10-18) 41 (38-45) <0.001 
Creatinine (mg/dl) 1.66±0.67 1.65±0.68 1.72±0.63 0.33 
LVEF (%) 63±10 57±21 53±23 0.17 
LVM/BSA (g/m2) 97.0±30.7 95.2±29.2 103.0±34.4 0.03 
LAV/BSA (mL/m2) 35.3±12.7 32.7±11.2 43.5±13.7 <0.001 
LAD (parasternal view; mm) 37.5±12.5 37.1±11.7 38.7±15 0.31 
Fractional Shortening (%) 38.0±8.2 38.4±7.9 36.8±9.1 0.12 
Anti-hypertensive drugs 
Diuretics n (%) 
Beta blockers n (%) 
 
356 (76) 
262 (56) 
 
260 (72) 
179 (50) 
 
96 (89) 
83 (77) 
 
<0.001 
<0.001 
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ARBs n (%) 
ACEi n (%) 
CCBs n (%) 
223 (48) 
200 (43) 
236 (50) 
161 (45) 
160 (44) 
184 (51) 
62 (57) 
40 (37) 
52 (48) 
0.021 
0.17 
0.57 
Etiology of CKD n. (%) 
Cystic diseases 
Diabetic nephropathy 
Glomerular diseases 
Nephroangiosclerosis 
Interstitial-/Pyelo-nephritis 
Other 
 
23 (5)  
43 (9) 
66 (14) 
189 (40) 
21(4) 
126 (27) 
 
22 (6) 
31 (9) 
54 (15) 
133 (37) 
21 (6) 
99 (27) 
 
1 (1) 
12(11) 
12(11) 
56(52) 
0 (0) 
 27(25) 
 
- 
0.43 
0.31 
0.006 
- 
0.61 
History of CV comorbidities n. (%) 
TIA n. (%) 
Peripheral vasculopathy n. (%) 
Coronary Stent n. (%) 
Myocardial Infarction n. (%) 
Stroke n. (%) 
141 (30) 
20 (4)  
29 (6) 
59 (13) 
52 (11) 
31 (7) 
98 (27) 
16 (4) 
21 (6) 
39 (11) 
34 (9) 
21 (6) 
43 (40) 
4 (4) 
8 (7) 
20 (18) 
18 (17) 
10 (9) 
0.01 
0.74 
0.55 
0.04 
0.04 
0.21 
 
Legend: ACEi, angiotensin converting enzyme-inhibitors; ARBs, angiotensin receptor blockers; BMI, body 
mass index; CCBs, calcium channel blockers; CV, cardiovascular; ePAP, estimated pulmonary artery pressure; 
LVEF, left ventricular ejection fraction; LVM/BSA, left ventricular mass indexed by body surface area; 
LAV/BSA, left atrial volume indexed by body surface area; LAD, left atrial diameter; TIA, transient ischaemic 
attack. 
 
 
2.2 Patients, Laboratory and Echocardiography assessment 
Blood samples were taken in fasting condition in the morning, and the second morning 
urine of the day was also collected. Common biochemical parameters were measured 
at baseline in all patients, according to standard methods in the clinical laboratories of 
the two cohorts. eGFR was assessed using the CKD-EPI creatinine (13) formula. Plasma 
samples were stored at −80 °C until batch analyses. All analyses were done blinded to 
clinical information. Patients’ history was carefully recorded by interview and 
confirmed by checking patients’ record, drug prescriptions included. All 
echocardiographic measurements were carried out according to the recommendations 
of the American Society of Echocardiography (14) by an observer unaware of 
biochemical results. Left ventricular ejection fraction (LVEF) was estimated by the 
Teichholz formula (15). Left ventricular mass (LVM) was calculated according to the 
Devereux formula (16) and indexed to body surface area (LVM/BSA). Left atrial volume 
was calculated from area-length method using apical 4-chamber and apical 2-chamber 
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(A2C) views, and indexed to body surface area (LAV/BSA). Left atrial diameter (LAD) was 
assessed by parasternal view. 
 
2.3 Pulmonary artery pressures evaluation 
Estimation of pulmonary artery systolic pressure (ePASP) was carried out by measuring 
maximal tricuspid regurgitation velocity (Vmax) and applying the modified Bernoulli’s 
equation (17) to convert this value into pressure values:  
 
ePASP= 4 x (Vmax2) + RAP 
 
Right atrial pressure (RAP) was estimated to be 10 mmHg or, in case of presence of a 
moderate or severe tricuspid regurgitation, 20 or 30 mmHg respectively.  High ePASP 
was defined according to an ePASP cut-off value of 35 mmHg (18). A sensitivity analysis 
adopting a more conservative threshold for the definition of high ePASP (>40 mmHg) 
was also performed. 
 
2.4 Prospective follow-up and study end-point 
The primary study outcome was a combined end-point including coronary, 
cerebrovascular and peripheral artery events, acute heart decompensation or 
cardiovascular death. All events required hospitalization and in both cohorts the same 
events were adjudicated after careful review of clinical files whenever needed. A 
detailed description on end-point definition in the MAURO and CARE FOR HOMe studies 
has been provided elsewhere (11, 12).  
 
2.5 Statistical analysis 
Normally distributed data were summarized as mean ± SD, non-normally distributed 
data as median and inter-quartile range, and binary data as percentage. Comparisons 
between groups were made by unpaired t-test, Mann-Whitney test or Chi Square Test, 
as appropriate. High ePASP was considered as categorical variable according to a cut-
off of ≥ 35 mmHg. Variables associated with high ePASP were identified by logistic 
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regression analyses. Variables associated with the combined endpoint were identified 
by univariate Cox’s regression and further tested by multivariate Cox regression 
analysis. Patients who progressed to stage 5D CKD during the follow up were 
maintained in all analyses, including the analysis of the combined end-point. In the 
multivariate analysis we included the set of variables (age, diabetes, hemoglobin, eGFR, 
LAV/BSA, LVM/BSA and CV comorbidities) that were associated (P<0.10) both with 
ePASP at logistic regression and with the combined outcome at Cox univariate analyses. 
A potential center effect was accounted for by data stratification. Data analysis was 
carried out by a commercially available statistical Package (SPSS for Windows, version 
21, New York, USA). 
 
3. RESULTS 
3.1 Patients baseline characteristics 
The main baseline characteristics of the study cohort are summarized in Table 1. Mean 
age of patients was 64±12 years and 60% (n=280) of them were male. One hundred 
sixty-five (35%) patients were diabetics and 59 (13%) were current smokers. One 
hundred forty-one patients (30%) had a history of cardiovascular disease, such as TIA, 
stroke, peripheral vascular disease or ischaemic cardiac disease. All patients had CKD 
stage 2-4. Mean serum creatinine was 1.66±0.67 mg/dl with a mean estimated GFR of 
45±18 mL/min/1.73 m2 (CKD-EPI). Mean systolic and diastolic BP were 150±25 and 
85±13 mmHg, respectively. Median albuminuria was 0.04 (IQR 0.007-0.21). Mean LVEF 
was 63±10%. Mean LVM/BSA, LAV/BSA and LAD were 97.0±30.7 g/m2, 35.3±12.7 mL/m2 
and 37.5±12.5 mm, respectively. High ePASP values (≥ 35 mmHg) were present in 23% 
(n=108) of patients in the study population and the prevalence of this alteration rose 
progressively across CKD stages (stage 2: 17%; stage 3: 24%; stage 4: 27%). In a 
sensitivity analysis adopting ePASP≥40 mmHg as criterion, the overall prevalence of 
high ePASP remained high (14%) and proportional to the degree of renal dysfunction 
(stage 2: 9%; stage 3: 15%; stage 4: 16%). The overall prevalence of mild to severe mitral 
or aortic valve disease was 6% (29/468): 7/108 (7.5%) in patents with high ePASP and 
22/360 (6.1%) in those without.  
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3.2 Univariate and multivariate logistic regression analyses of high ePASP 
On univariate logistic regression, the presence of high ePASP was significantly 
associated with age (OR 1.08; 95% CI 1.05-1.10; p=0.001), diabetes mellitus (OR 1.58; 
95% CI 1.02-2.45; p=0.04), haemoglobin (OR 0.78; 95% CI 0.68-0.90; p<0.001), eGFR (OR 
0.98; 95% CI 0.97-0.99; p=0.01), LVM/BSA (OR 1.01; 95% CI 1.01-1.02; p=0.02), LAV/BSA 
(OR 1.07; 95% CI 1.05-1.09; p<0.001) and history of cardiovascular disease (OR 1.77; 
95% CI 1.13-2.77; p=0.01). In a multivariate regression model including all univariate 
associated, only age (OR 1.06; 95% CI 1.04-1.09; p<0.001) and LAV/BSA (OR 1.05; 95% 
CI 1.03-1.07; p<0.001) maintained a statistically significant association with high ePASP 
values. Data on logistic regression models are reported in Table 2. 
 
Table 2. Univariate and multivariate logistic regression analysis of high ePASP (≥ 35 mmHg) 
 
 Variable 
Univariate Multivariate 
OR (95% CI) p OR (95% CI) p 
Age (years) 1.08 (1.05-1.10) 0.001 1.06 (1.04 -1.09) <0.001 
Diabetes mellitus (yes/no) 1.58 (1.02-2.45) 0.04 1.18 (0.70-1.96) 0.53 
Haemoglobin (g/dl) 0.78 (0.68-0.90) <0.001 0.89 (0.75-1.06) 0.20 
CKD-EPI (mL/min/1.73 m2) 0.98 (0.97-0.99) 0.01 1.00 (0.98-1.02) 0.89 
LVM/BSA (mL/m2) 1.01 (1.01-1.02) 0.02 1.00 (0.99-1.01) 0.74 
LAV/BSA (g/m2) 1.07 (1.05-1.09) <0.001 1.05 (1.03-1.07) <0.001 
History of CV disease (yes/no)  1.77 (1.13-2.77) 0.01 0.81 (0.46-1.41) 0.45 
 
 
3.3 Cardiovascular combined endpoint during the follow-up period 
During follow-up (median: 3.0 years; IQR 1.9-3.8), 76 subjects (16%) reached the 
composite endpoint. In particular, 11 subjects died due to CV events (6 arrhythmia, 1 
ischaemic cardiomyopathy and 4 cardiac decompensation) while 65 subjects had a non-
fatal CV event (25 coronary events, 2 arrhythmia, 11 cerebrovascular disease, 16 cardiac 
decompensation, 11 peripheral vascular disease). Data on separate outcomes in 
patients with or without high ePASP are shown in Table 3. Kaplan-Meier survival curves 
for the combined endpoint in patients with or without high ePASP are presented in 
Figure 2. Patients with high ePASP experienced a significantly faster evolution to the 
combined endpoint (crude HR 2.70; 95% CI 1.68-4.32; p<0.001 Log-rank test; χ2 18.06). 
Results remained substantially unchanged when the 11 deaths were censored 
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(p<0.001; Log-rank test; χ2 26.48). Interestingly, exploratory ROC curves showed that 
the optimal ePASP value for discriminating patients reaching the endpoint was nearly 
identical to the currently recommended high ePASP echocardiographic cut-off adopted 
in this study (36 vs 35 mmHg; Figure 3).  
 
Table 3. Data on separate cardiovascular events in patients with ePASP<35 mmHg or ≥35 mmHg. 
 
Separate CV events n ePASP<35 ePASP≥35 
Coronary 26 14 12 
Arrythmia 8 4 4 
Cerebrovascular 11 8 3 
Cardiac decompensation 20 14 6 
Peripheral vascular disease 11 6 5 
Total 76 46 30 
 
 
Figure 2. Kaplan-Meier survival curves for the combined CV endpoint in patients with ePASP ≥ 35 mmHg or 
ePASP < 35 mmHg.  
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Figure 3. ROC curves comparing the optimal ROC-derived ePASP value (36 mmHg) to the currently suggested 
echocardiographic cut-off for high ePASP (35 mmHg) for discriminating patients reaching the endpoint. 
 
 
3.4 Cox’s regression models for the cardiovascular combined endpoint 
At univariate Cox regression models, high ePASP, older age, presence of diabetes 
mellitus, lower hemoglobin, higher LAV/BSA, higher LVM/BSA, history of CV 
comorbidities, and lower eGFR all predicted adverse cardiovascular outcomes (Table 
4). In analyses adjusting for baseline associated to high ePASP (p<0.10) and including all 
univariate predictors of the combined end-point only high ePASP (HR 1.75; 95% CI 1.05- 
2.91; p=0.03), diabetes mellitus (HR 1.61; 95% CI 1.02-2.54; p=0.04), LAV/BSA (HR 1.02; 
95% CI 1.01-1.04; p=0.04), history of CV disease (HR 3.63; 95% CI 2.18-6.05; p<0.001) 
and eGFR (HR 0.97; 95% CI 0.96-0.99; p<0.001) maintained an independent relationship 
with the same combined end-point. In these adjusted analyses LVM/BSA, haemoglobin 
levels and age were no longer associated with the incidence of the combined end-point 
(Table 4). 
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Table 4. Cox proportional hazards regression models for the combined outcome.  
 
Variable 
Units of 
increase 
Univariate Multivariate 
HR 95% CI p HR 95% CI p 
ePASP ≥ 35 mmHg yes/no 2.70 
1.68 to 
4.32 
<0.001 1.75 
1.05 to 
2.91 
0.03 
Age  1 year 1.05 
1.03 to 
1.07 
<0.001 1.01 
0.98 to 
1.03 
0.50 
Diabetes mellitus yes/no 1.91 
1.21 to 
3.00 
0.005 1.61 
1.02 to 
2.54 
0.04 
Haemoglobin  g/dl 0.77 
0.67 to 
0.88 
<0.001 0.91 
0.78 to 
1.07 
0.26 
CKD-EPI 
mL/min/1.73 
m2 
0.96 
0.95 to 
0.98 
<0.001 0.97 
0.96 to 
0.99 
<0.001 
LAV/BSA  mL/m2 1.04 
1.03 to 
1.06 
<0.001 1.02 
1.01 to 
1.04 
0.04 
LVM/BSA  g/m2 1.01 
1.01 to 
1.02 
<0.001 1.01 
1.00 to 
1.01 
0.06 
History of CV disease yes/no 5.00 
3.13 to 
8.01 
<0.001 3.63 
2.18 to 
6.05 
<0.001 
 
Forcing albuminuria and the use of ACEi, ARBs, CCBs, beta-blockers and diuretics into the model, ePASP≥35 
mmHg remained significantly associated to the combined outcome (HR 2.01; 1.18-3.43, p=0.01). 
 
4. DISCUSSION 
In this study in a population of pre-dialysis CKD of various severity, from stage 2 to stage 
4, high pulmonary artery systolic pressure as assessed by echocardiography was 
present in about ¼ of patients and predicted adverse cardiovascular outcomes 
independent of background cardiovascular events, LVH and other major risk factors in 
this population. Overall the present data extend to mild to moderate CKD stages 
observations made in dialysis patients. The prevalence of high ePASP by 
echocardiography was estimated in two large population based studies, the Olmsted 
county study (19) and the Armadale echocardiography study (20). In both studies the 
prevalence of high ePASP was unexpectedly high being about 5% in the first study and 
9.1%, in the second study. The vast majority of patients with high ePASP in these large 
surveys had concomitant cardiac disease and resulting LV dysfunction.  
In patients with advanced, stage 5 CKD before or after initiation of dialysis, the 
prevalence of high ePASP largely exceeds estimates in the general population, ranging 
from 9% to 39% in patients maintained on conservative treatment and from 18.8% to 
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68.8% in patients on chronic renal replacement therapy (7) suggesting that CKD severity 
may trigger and/or worsen the increase in ePASP. Our observations indicate that high 
ePASP is exceedingly prevalent also in CKD patients with less advanced renal 
dysfunction (K-DOQI stages 2-4), being as high as 23% by the ePASP>35 mmHg criterion 
and 14% by the ePASP>40 mmHg criterion. A very recent study in 101 Chinese patients 
with CKD stage 1-3 reported a 23.7% prevalence (8), a value very close to that observed 
in our cohort by adopting the ePASP>35 mmHg criterion. Multiple risk factors may be 
implicated in the high prevalence of elevated PASP values in CKD. In the present study, 
high ePASP was associated with age, low GFR, high left atrial volume, low hemoglobin 
and major comorbidities such as diabetes and background CV disease. As expected in 
pre-dialysis CKD patients, anemia was of mild to moderate degree which may help to 
explain the fact that this risk factor had no independent relationship with pulmonary 
pressure. Sleep apnea (21), increased sympathetic activity and high levels of the 
endogenous inhibitor of NO synthase Asymmetric Dimethyl-arginine (ADMA) are 
implicated in pulmonary hypertension (PH) in individuals with primary forms of 
pulmonary artery hypertension (22, 23). The relationship of these factors with high 
ePASP in CKD patients needs to be investigated in specifically designed studies in this 
population. Elevated pulmonary pressure was associated with high pulse pressure in 
the Olmsted study (19) suggesting that stiffening of the pulmonary artery might in part 
explain high pulmonary pressure in the general population. Although increased arterial 
rigidity is one of the main features of CKD (24), we did not observe an association 
between pulse pressure and pulmonary pressure, suggesting that the contribution of 
arterial stiffening to high pulmonary pressure in earlier CKD stages is of limited 
importance. In the general population, primary or secondary left ventricular disorders 
are the most common triggers of pulmonary hypertension (19) and up to 60% of 
patients with severe LV systolic dysfunction and up to 70% of patients with isolated LV 
diastolic dysfunction may have concomitant PH (25). In our study high ePASP strongly 
associated to higher LV mass index and larger left atrial volume, and the association 
with left atrial volume remained significant even after adjustment for potential 
confounders. These findings, which are in keeping with previous studies of PH in dialysis 
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patients (9, 26-28) support the hypothesis that in most cases PH in CKD is post-capillary 
in nature (29), i.e. that it depends on passive congestion of the venous side of the 
pulmonary vasculature rather than by an increase in pulmonary artery vascular 
resistances. Subtle or clinically manifest volume expansion, a hallmark of CKD, together 
with LV diastolic dysfunction, is a relevant determinant of left atrial volume (30) and 
therefore may contribute to raise pulmonary pressure in CKD patients. As most relevant 
finding of our study, high ePASP emerged as a strong predictor of a combined end-point 
including fatal and non-fatal CV events. Indeed, independently of other risk factors, CKD 
patients with ePASP≥35 mmHg had a 75% risk excess for developing the combined 
endpoint as compared to those with ePASP<35 mmHg. Overall, our data extend to 
earlier CKD stages observations made in two cohort studies among dialysis patients (28, 
31). Our study has several limitations. The main limitation is the fact that we estimated 
PASP by echocardiography. Echocardiographic estimates of PASP are just an 
approximation of the true (directly measured) pulmonary artery systolic pressure. 
However, echocardiography is considered an acceptable approach for investigating 
PASP in large scale epidemiologic studies (19, 20) and the criteria for estimating PASP 
and for defining elevated ePASP adopted in the present study are identical to those 
adopted in the largest studies in the general population (19, 20). Although high ePASP 
above 35 mmHg may reflect the true presence of PH, guidelines recommend that the 
diagnosis of PH should be confirmed by a direct measurement of pulmonary pressure 
(18). Until now, direct pulmonary pressure measurement in CKD was performed in a 
single study including 31 hemodialysis patients and 31 stage 5 CKD patients before 
starting dialysis treatment (29). The overall prevalence of PH in this series was very high 
(81%), which may reflects selection bias, as patients were selected for invasive 
measurement of pulmonary pressure because of the presence of dyspnea unexplained 
by concomitant cardio-pulmonary diseases. Although the combined data-base of our 
two cohorts was fairly large and based on standardized echocardiographic criteria, the 
prevalence of high ePASP we found cannot be generalized to the CKD population at 
large. Further studies in other ethnical groups will be needed to allow solid estimates 
of such prevalence in early CKD patients. Finally, as expected in an early to moderate 
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CKD population, the rate of CV death (2.3%) and non-fatal CV events (13.8%) was 
relatively low. Overall the number of clinical events was insufficient to perform 
separate analysis of mortality and relevant cardiovascular outcomes. In conclusion, we 
observed a high prevalence of elevated PASP as assessed by echocardiography among 
patients with CKD stage 2-4. The presence of high ePASP independently predicts 
adverse CV outcomes, even after adjustment for CV risk factors, eGFR, prevalent 
cardiovascular disease and echocardiographic markers of left heart disease. Our 
findings need to be confirmed in studies adopting invasive measurements of PASP in 
patients with high ePASP as indicated by echocardiographic screening. Future studies 
should address the issues whether CKD patients with high ePASP should undergo 
further investigations, and whether tailored therapeutic approaches to normalize 
pulmonary pressure will beneficially affect their outcome. 
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ABSTRACT 
Background: Vascular ageing is known to induce progressive stiffening of the large 
elastic arteries, altering vascular hemodynamics under both rest and stress conditions. 
In this study, we aimed to investigate changes in vascular hemodynamics in response 
to isometric handgrip exercise across ages.  Methods: We included 62 participants, 
divided into three age categories: 20-40 (n=22), 41-60 (n=20) and 61-80 years (n=20). 
Vascular hemodynamics were measured using the Mobil-o-Graph based on the 
pulsatile pressure changes in the brachial artery. One-way ANOVA test was performed 
to analyze the changes induced by isometric handgrip exercise. Results: After isometric 
handgrip exercise, aortic PWV increased by 0.10 m/s in the youngest, 0.06 m/s in the 
middle age and 0.02 m/s in the oldest age category. Changes in PWV strongly correlated 
with those in cSBP (r=0.878, p<0.01). After isometric exercise mean change of SBP was 
-1.978% in the youngest, 0.61.27% in the middle-aged and 8.27.24% in the oldest 
subjects. in the oldest subjects. Increasing handgrip strength was associated with an 
increase in SBP and cSBP (respectively 1,08 and 1,37 mmHg per 1 kg increase in 
handgrip strength, P=0.01). Finally, PWV was significantly associated with increasing 
handgrip strength with an increase of 0.05 m/s per 1 kg higher increased handgrip 
strength (P=0.01). Conclusion: This study found increased blood pressure levels after 
isometric challenge and a strong association between handgrip strength and change in 
blood pressure levels and aortic stiffness in elderly subjects. 
 
Key words:  vascular aging, isometric stress, blood pressure, pulse wave velocity 
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1.INTRODUCTION 
During isometric exercise, the autonomic nervous system elicits a cardiovascular 
response by an increase in the sympathetic nerve activity. Two neural systems 
contribute to sympathetic activation: the ‘central command’ and the ‘exercise pressor 
reflex’ (1). Signals arising in the motor cortex activate both the cardiovascular control 
areas, to modulate sympathetic and parasympathetic activity, and skeletal muscle 
contraction (2). The exercise pressor reflex (or muscle reflex) is generated by 
contraction of skeletal muscle via mechanically (muscle mechanoreflex) and chemically 
(muscle metaboreflex) skeletal muscle receptors (3). During handgrip exercise the 
pressor reflex occurs when the muscle fatigues and/or when there is a mismatch 
between blood supply and metabolic demand (4). While the increase in arterial 
pressure during isometric exercise is a well-established response (5), the response of 
other vascular hemodynamics to exercise, such as arterial stiffness, is yet unclear. Age 
is the most important determinant for changes in the cardiovascular system. Vascular 
aging results in loss of elastic properties, which leads to progressive stiffness of the large 
elastic arteries (6). Several studies have shown that arterial stiffness is an independent 
predictor of chronic heart disease (7,8), stroke (8,9), all-cause mortality and 
cardiovascular mortality (10) in hypertensive patients and it is associated with increased 
risk for cardiovascular events in the general population (11,12). Measurement of pulse 
wave velocity (PWV) is the leading noninvasive method of assessing arterial stiffness 
which is calculated by dividing the pulse distance travelled by the time travelled (13). 
Data on the effects of isometric exercise on arterial stiffness are limited. Several studies 
found an increase in central large artery stiffness in response to isometric handgrip 
exercise in hypertensive (14) and healthy participants (14-16) suggesting that the 
increase in arterial stiffness could be due to the increased vasoconstriction from 
sympathetic system activation. However, these studies included participants within a 
range of age between 30-54 years. Since age is an important determinant for stiffening 
of the elastic arteries, it is interesting to explore the effect of aging on vascular 
hemodynamics in response to isometric exercise. We hypothesized that changes might 
be more pronounced in elderly compared to young adults due to an altered autonomic 
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response. Therefore, we investigated the changes in vascular hemodynamics in 
response to isometric handgrip exercise in persons of different ages. 
 
2. METHODS  
2.1 Subjects  
We included 62 participants aged 20-80 years. The participants were students, 
employees and apparently healthy patients from the section of Geriatric Medicine of 
the Erasmus University Medical Center. Informed consent was obtained from all 
participants and the study was approved by the local Medical Ethics Committee of the 
Erasmus MC (MEC 2014-336).  
 
2.2 Protocol 
The participants entered the room and were instructed to assume a supine position. An 
inflatable cuff was placed on the dominant arm. After five minutes of rest, baseline data 
were acquired using the Mobil-o-Graph device. Patients were asked to perform 
maximum hand grip trial in the standing position with their arms along their body. 
Maximal hand grip strength was the highest score recorded. Hand Grip strength was 
measured using a strain-gauged dynamometer (Takei, TKK 5401, Takei Scientific 
instruments Co. Ltd., Japan). Participants performed a maximum voluntary contraction 
using a handgrip dynamometer held in the dominant hand during 30 seconds. After 30 
seconds of rest, the vascular hemodynamics were measured.   
 
2.3 Measurements 
The Mobil-o-Graph is an oscillometric blood pressure measurement validated device 
able to measure vascular hemodynamics such as central and peripheral blood pressure, 
augmentation index (AIx) and pulse wave velocity (PWV) (17). Measurements of PWV 
and AIx are based on the pulsatile pressure changes in the brachial artery. The pressure 
cuff sensors the first systolic peak of the pulse wave which corresponds to the ejection 
of the blood volume into the aorta. The second systolic peak represents the reflection 
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of the pulse wave from the periphery. PWV can be calculated by dividing the difference 
in time, between the beginning of the first and second systolic peak, and the distance 
from the jugular notch to the symphysis. Augmentation index is the difference of the 
amplitudes of the first and second systolic peak. Estimates of PWV are derived using 
ARC Solver algorithms.  
 
2.4 Statistical analysis 
All descriptive data are reported as mean ± SE. Differences in baseline hemodynamics 
were investigated by ANOVA. We investigated possible changes of blood pressure 
levels, heart rate, cardiac output, total peripheral resistance, augmentation index and 
pulse wave velocity induced handgrip exercise with two-way ANOVA analyses in the 
three different categories of ages with models adjusted for age, sex and the baseline 
corresponding hemodynamic value (ie baseline systolic blood pressure was included in 
models investigating changes of systolic blood pressure levels). We investigated 
correlations between hemodynamic changes and handgrip strength with the linear 
regression. The level of significance was taken as p < 0.05. Analysis were performed 
using IBM SPSS Statistics for Windows, Version 21.0.  
 
3. RESULTS 
Table 1 shows the mean values for the characteristics of the participants. Mean age of 
the youngest, middle-aged and oldest subjects was respectively: 28,8 ± 5,5 years, 49,8 
± 5,9 years and 71,0 ± 5,6 years. The results of the hemodynamic measurements at 
baseline are presented in Table 2. We found a statistically significant difference in PWV 
(P for trend < 0.01) and in pulse pressure between groups (P for trend < 0.05) at 
baseline. No differences were found in systolic or diastolic blood pressure between 
groups. There was no difference in maximum handgrip strength between groups with 
respectively 31,2± 5 kg in the youngest, 32,5± 2.2 kg in the middle-aged and 29,7± 5.4 
kg in the oldest subjects (P for trend = 0.748). Changes in vascular hemodynamics 
induced by isometric handgrip exercise. Figure 1 presents the changes in hemodynamic 
parameters after handgrip exercise. After isometric exercise mean change of SBP 
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(Figure 1A) was -1.9% in the youngest, 0,6% in the middle-aged and 8.2% in the oldest 
subjects. The differences in mean change of SBP between the youngest, middle aged 
and oldest participants were statistically different (p= 0.03) and (p= 0.01) respectively. 
The mean change in DBP (Figure 1B) after handgrip exercise was 0,7% in the youngest, 
0,3 % in the middle-aged and 6.9% in the oldest subjects. The difference in mean change 
of DBP between middle aged and oldest participants was significant (P < 0.02). We 
found no difference in mean change of PP (Figure 1C) and heart rate (Figure 1D) 
between the youngest, middle-aged and oldest subjects with respectively -9%, -1% and 
14.%. The mean change in augmentation index (Figure 1E) after handgrip exercise was 
-50 % in the youngest, 35 % in the middle-aged and 80 % in the oldest subjects. The 
difference in mean change of augmentation index between young and oldest subjects 
was statistically significant (P < 0.046). After isometric exercise all subjects shown a non-
significant decrease in CO (Figure 1F) and a non-significant increase in total peripheral 
resistance (TPR) (Figure 1G). No difference was found in mean change of PWV after 
handgrip between subjects with -0,83% in the youngest, 1.0% in the middle-aged and 
2.21% in the oldest subjects. Relationship between handgrip strength and changes in 
vascular hemodynamics. Table 3 shows the association between handgrip strength and 
vascular hemodynamics, in the youngest, middle-aged and oldest subjects. In the 
youngest and middle-aged subjects, we found no association between handgrip 
strength and change in vascular hemodynamics. We found an association between 
handgrip strength and the change in SBP, PP, cSBP, cPP and PWV in the oldest subjects. 
Increasing handgrip strength was associated with an increase in SBP and cSBP 
(respectively 1,08 and 1,37 mmHg per 1 kg higher in handgrip strength, P=0.01). This 
means that per 10 kg handgrip strength, SBP and cSBP, increase with 10,8 mmHg and 
13,7 mmHg. The association between increasing handgrip strength and the change in 
PP and cPP was also significant (P=0.01). With an increase of 1 kg handgrip strength, PP 
increased with 1,19 mmHg while cPP increased with 1,46 mmHg. Finally, PWV was 
significantly associated with increasing handgrip strength with an increase of 0.05 m/s 
per 1 kg increased handgrip strength (P=0.01). 
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Table 1. Clinical characteristics of study participants 
Variables   
(mean ± SD) 
Age 20-40  
(n=22) 
Age 41-60  
(n=20) 
Age 61-80  
 (n=20) 
Age, years 28,8 ± 5,5 49,8 ± 5,9 71,0 ± 5,6 
Sex, male 50 % 50 % 60 % 
Height, cm 175 ± 10 171 ± 16 173 ± 10 
Weight, kg 76 ± 13 83 ± 27 80 ± 14 
Body mass index, kg/m2 24,7 ± 4,1 25,9 ± 3 26,7 ± 4,3 
 
Table 2. Hemodynamic parameters at baseline           
Variables  
(mean ± SD) 
Age 20-40 yrs  
(n=22) 
Age 41-60 yrs 
(n=20) 
Age 61-80 yrs 
(n=20) 
P value * 
 Systolic BP, mm Hg  119 ± 7,9 123 ± 3,4 132 ± 8,4 0.59 
Diastolic BP, mm Hg 80 ± 4,6 81 ± 2,0 76 ± 4,9 0.46 
Pulse pressure, mm Hg 39 ± 5,3 42 ± 2,3 56 ± 5,6 0.05 
MAP, mm Hg 95 ± 9 100 ± 11 105 ± 14 0.96 
Heart rate, bpm 68 ± 4,6 60 ± 2,0  62 ± 4,9 0.17 
Central systolic BP, mm Hg 111 ± 7,5 115 ± 3,3 124 ± 8,0 0.54 
Central diastolic BP, mm Hg 80 ± 4,6 82 ± 2,0 77 ± 4,9 0.45 
Central pulse pressure, mm Hg 31 ± 5,0 33 ± 2,2 47 ± 5,4 0.03 
Augmentation index @75, % 12 ± 8,3 25 ± 3,6 24 ± 8,8 0.24 
Cardiac output, l/min 5,2 ± 0,5 4,6 ± 0,2 5,0 ± 0,5 0.09 
TPR, s*mmHg/min 1,08 ± 0,22 1,36 ± 0,23 1,35 ± 0,27 0.10 
Aortic PWV, m/s 7,6 ± 0,3 7,0 ± 0,1 8,2 ± 0,3 0.00 
Handgrip strength, kg 31,2 ± 5,0 32,5 ± 2,2 29,7 ± 5,4 0.75 
 
* P value for trend; BP, blood pressure; MAP, mean arterial pressure; TPR, total peripheral resistance ; PWV, 
pulse wave velocity 
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Table 3. Delta hemodynamic parameters as determinant of handgrip strength in the youngest, middle-aged 
and oldest subjects              
 
 Age 20-40 years 
(n= 22) 
Age 41-60 years 
(n=20) 
Age 61-80 years 
(n=20) 
Handgrip (Kg) B SE P value B SE P value B SE P value 
 ∆ SBP, mmHg 0,20 0,12 0,12 0,15 0,16 0,34 1,08 0,36 0,01* 
 ∆ DBP, mmHg -0,04 0,10 0,71     0,09 0,09 0,31 -0,10 0,23 0,66 
∆ PP, mmHg 0,24 0,14 0,11  0,06 0,14 0,65 1,19 0,40 0,01* 
∆ Heart rate, bpm -0,00 0,11 0,99 -0,02 0,06 0,70 0,12 0,34 0,74 
∆ cSBP, mmHg 0,16 0,20 0,44  0,20  0,16 0,23 1,37 0,44   0,01* 
∆ cDBP, mmHg -0,02 0,10 0,82  0,07 0,09 0,48 -0,07 0,21 0,76 
∆ cPP, mmHg 0,18 0,20 0,38 0,12 0,18 0,51 1,46 0,49 0,01* 
∆ AIx @75, % 0,41 0,57 0,48 0,57 0,41 0,18 -0,32 1,19 0,79 
∆ CO, L/min -0,03 0,03 0,29 -0,00 0,02 0,89 0,02 0,06 0,72 
∆ TPR, 
s*mmHg/min 
0,01 0,01 0,24 0,00 0,01 0,86 0,00 0,02 0,91 
∆ PWV, m/s 0,01 0,01 0,19 0,01 0,01 0,20 0,05 0,02 0,01* 
 
*, P value <0.05; B, Beta; SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, 
pulse pressure; c, central; AIx, augmentation index; CO, cardiac output; TPR, total peripheral resistance; PWV, 
pulse wave velocity 
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Figure 1. Change in systolic blood pressure (A), diastolic blood pressure (B), pulse pressure (C), heart rate (D), 
augmentation index (E), cardiac output (F), total peripheral resistance (G) and pulse wave velocity (H) before 
and after handgrip exercise. 
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4. DISCUSSION 
In the present study we found increased blood pressure levels after isometric challenge 
in elderly subjects. We also found a strong association between handgrip strength and 
change in blood pressure levels and aortic stiffness in the older subjects; we did not 
observe this association in the youngest or middle-aged subjects. Previous studies have 
shown an increase of blood pressure levels after isometric handgrip exercise in 
normotensive and hypertensive individuals (14), in healthy young subjects (16,18,19) 
and older subjects (20) who also observed that hemodynamic changes can considerably 
vary among individuals (18). Within the framework of a relatively large community-
based longitudinal study, Taekema et al. (21) investigated the possible relation between 
blood pressure and handgrip strength in middle-aged (63 years) and old subjects (85 
years). finding an association between handgrip strength and high SBP, PP only in the 
oldest subjects. According to Taekema we also found increased blood pressure levels 
after isometric challenge to be more pronounced in elderly subjects, moreover we 
found a strong association between handgrip strength and aortic stiffness. Several 
mechanisms can explain our results. First, the observed changes in blood pressure in 
the elderly can be explained due to failure of the aging arterial system during stress. 
During isometric exercise, the autonomic nervous system elicits a cardiovascular 
response which increases sympathetic nerve activity, arterial blood pressure and heart 
rate, and changes the distribution of blood flow. The arterial system in younger subjects 
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is capable of receiving spurts from the left ventricle of blood during isometric exercise 
and distribute these trough peripheral capillaries. Elastin fibers in the arterial wall 
minimize the fluctuations in the blood flow. Vascular ageing results in loss of elastic 
properties, which leads to progressive stiffness of the large elastic arteries. Stiffening 
leads to an increase of systolic pressure and a decrease in diastolic pressure which 
stresses the small arterial vessels causing damage to particularly the coronary arteries, 
kidney and brain (22). We found a statistically significant increase in pulse pressure and 
aortic stiffness with increasing age at baseline. We found significant differences in the 
change of SBP and DBP after exercise between the middle-aged and oldest subjects 
with more pronounced changes in the oldest subject. The present study has some 
limitations. First, we included a relatively small number of participants. Second, we 
performed measurements only once so we cannot exclude variation over time. Strength 
of this study is that we performed our measurements following standard procedure, in 
this way we think that exposure was similar for all participants. Moreover, we used a 
brachial cuff-based oscillometric device which has been shown to be reproducible (23), 
acceptable accurate when compared with other invasive methods (24) and useful for 
routine clinical practice (25). In conclusion, we found increased blood pressure levels 
after isometric challenge and a strong association between handgrip strength and 
change in blood pressure levels and aortic stiffness in elderly subjects. These findings 
can be possibly explained by failure of the aging arterial system during stress and 
increased vascular resistance with increasing age.  
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ABSTRACT 
Background/Aims: Scarce physical activity predicts shorter survival in dialysis patients. 
However, the relationship between physical (motor) fitness and clinical outcomes has 
never been tested in these patients. Methods: We tested the predictive power of an 
established metric of motor fitness, the Six-Minute Walking Test (6MWT), for death, 
cardiovascular events and hospitalization in 296 dialysis patients who took part in the 
trial EXCITE (ClinicalTrials.gov Identifier: NCT01255969). Results: During follow up 69 
patients died, 90 had fatal and non-fatal cardiovascular events, 159 were hospitalized 
and 182 patients had the composite outcome. In multivariate Cox models - including 
the study allocation arm and classical and non-classical risk factors - an increase of 20 
walked metres during the 6MWT was associated to a 6% reduction of the risk for the 
composite end-point (P=0.001) and a similar relationship existed between the 6MWT, 
mortality (P<0.001) and hospitalizations (P=0.03). A similar trend was observed for 
cardiovascular events but this relationship did not reach statistical significance (P=0.09).  
Conclusions: Poor physical performance predicts a high risk of mortality, cardiovascular 
events and hospitalizations in dialysis patients. Future studies, including phase-2 
EXCITE, will assess whether improving motor fitness may translate into better clinical 
outcomes in this high risk population. 
 
Key Words: Physical performance, Six-minute walking test, Chronic kidney disease, 
Dialysis, Clinical Outcomes 
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1. INTRODUCTION 
Physical activity and physical performance are notoriously poor in patients with end-
stage kidney disease (ESKD) (1), a population with an extremely high risk of death and 
cardiovascular events (2). Even though representing strictly related phenomena, 
physical activity and physical performance are separated entities with different metrics. 
Physical activity, i.e. physical engagement in daily activities, is a well-established 
predictor of mortality and cardiovascular events in the general population (3) and in 
pathological conditions such as diabetes (4) and coronary artery disease (5) and in end 
stage kidney disease (ESKD) as well (6-9). To our knowledge, the relationship between 
actual physical performance, i.e. the objectively measured ability to perform well 
standardized physical efforts, and clinical outcomes in ESKD has been investigated just 
in a small study with a very limited number of major clinical events (just 21 deaths) (10). 
The Six-Minute Walking Test (6MWT) is an established test to assess physical 
performance in frail elderly patients (11), and this test has been applied in clinical 
studies in various conditions, such as heart failure (12, 13) and chronic obstructive 
pulmonary disease (COPD) (14). The EXCITE (EXerCise Introduction To Enhance 
Performance in Dialysis) study, is a large, multicentre, randomized trial whose phase – 
2 (clinical outcomes and hospitalization) is still in progress. This study tests the 
effectiveness of an easy-to-implement program of physical training in dialysis patients. 
We have taken the opportunity of the EXCITE study to investigate the relationship 
between actual physical performance, as assessed by the Six-Minutes Walking Test, on 
mortality, cardiovascular events and hospitalizations in dialysis patients. 
 
2. PATIENTS AND METHODS 
The study protocol was approved by the ethical committee of our institution. All 
participants gave informed consent before enrolment. 
 
2.1 Patients 
The EXCITE Study is a multicentre randomized controlled trial on the effectiveness of 
exercise in improving physical performance and the quality of life (phase-1) and in 
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reducing adverse clinical outcomes (mortality, cardiovascular events and 
hospitalizations) (phase-2) in dialysis patients. This trial is registered in ClinicalTrials.gov 
(Identifier: NCT01255969). In this secondary analysis, we included 296 dialysis patients 
who performed the 6MWT at baseline. These patients had been on regular dialysis (HD 
or PD) for a median time of 44 months (inter-quartile range: 26-83). haemodialysis 
patients (n=247) were being treated with standard bicarbonate dialysis with non-
cellulosic membrane filters of various type. PD patients (n=49) were either on 4 
standard exchanges day (n=11) or on continuous cycling peritoneal dialysis (n=38). Two 
hundred and six patients were treated with various anti-hypertensive drugs (76 on 
mono-therapy with calcium channel blockers, ACE inhibitors, sartans, alpha or beta 
blockers, clonidine, furosemide, 65 on double therapy, 44 on triple therapy and 21 
patients on quadruple and quintuple therapy with various combinations of these 
drugs). The main demographic, somatometric, clinical and biochemical characteristics 
of the study population are detailed in Table 1. 
 
2.2 Laboratory measurements 
Blood sampling was performed after an overnight fast. In haemodialysis patients, blood 
was always drawn in the morning hours (8 am – 12 am) during a mid-week day (brief 
dialysis interval). Serum cholesterol, albumin, calcium, phosphate, C-Reactive Protein 
(CRP) and haemoglobin measurements were made using standard methods in the 
routine clinical laboratory. Six-Minute Walking Test Physical performance was assessed 
at baseline with the Six-Minute Walking Test (6MWT). This test consists in a 6 minute-
walk along a marked walkway on a hard, flat surface, at the maximum speed that each 
patient can maintain. The goal of this test is to walk as far possible in six minutes. During 
the walk, the patient is allowed to stop and rest whenever he/she wants, and the 
number of interruptions are carefully recorded by an operator. At the end of the test, 
the fatigue perceived by the patient is classified by the Borg Scale, a simple method that 
allows to rate the perceived exertion by using a scale from 0 (no exertion) to 10 
(maximum exertion)  
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Table 1. Main demographic, somatometric and clinical characteristics in the study population and correlates 
of Six-Minute Walking Test (6MWT) 
 
 
 
2.3 Study end-points 
In this secondary analysis of EXCITE, a composite end-point including mortality, fatal 
and non-fatal cardiovascular events and hospitalizations was the main study end-point. 
Cardiovascular events were classified as follows: stroke (ischemic or haemorrhagic) 
documented by computed tomography, magnetic resonance imaging and / or clinical 
and neurological evaluation; transient ischemic attacks (TIA); myocardial infarction 
confirmed by serial changes of ECG and cardiac biomarkers; ECG-documented angina 
episodes; heart failure, diagnosed according to criteria by the AHA guideline (15); ECG 
documented arrhythmia; peripheral ischemia or amputations; unexpected, sudden 
death highly suspected as of cardiac origin. Hospitalizations were classified in 
cardiovascular and non-cardiovascular using information included in the hospital 
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records. Cause of death was assessed by 3 independent physicians. In doubtful cases, 
diagnosis was attributed by consensus. During the review process, involved physician 
used all available medical information, including hospitalization forms and medical 
records. In case of death occurred at home, family members and/or general 
practitioners were interviewed to better understand the circumstances surrounding 
death. 
 
2.4 Statistical analysis 
Data were expressed as mean ± standard deviation (normally distributed data), median 
and inter quartile range (non-normally distributed data) or as per cent frequency 
(categorical data). The Person correlation coefficient was used to describe correlates of 
6MWT variable. The independent correlates of 6MWT were identified by correlation 
analysis and by multiple linear regression. Tested variables included age, gender, 
smoking, cardiovascular comorbidities, diabetes, antihypertensive therapy, Body Mass 
Index (BMI), dialysis vintage, systolic and diastolic blood pressure, cholesterol, albumin, 
C-reactive protein, calcium, phosphate, haemoglobin and NYHA class. All variables 
which correlated with 6MWT (with P<0.05) were jointly introduced into the same 
model. Survival analyses were performed by using bivariate and multivariate Cox 
regression models. In close parallelism with the strategy used for the identification of 
independent correlates of 6MWT (see above), in the multiple Cox Regression model we 
included all univariate correlates of the combined end point (with P<0.05). Statistical 
analysis was performed by using standard statistical packages (SPSS for Windows, 
Version 20, Chicago, Illinois, USA; STATA for Windows, Version 13, College Station, 
Texas, USA).  
 
3. RESULTS 
The flow-chart describing the recruitment basis of the study population and the 
subsequent selection process, from eligibility to randomisation, is reported in Figure 1 
and the baseline characteristics of patients randomised to the study intervention are 
described in Table 1. Enrolled patients had a mean age of 65 years. Sixty-eight of them 
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were male, 17% were current smokers, 26% were past smokers. Twenty-one per cent 
of patients were diabetics and 76% had cardiovascular comorbidities. 
 
Figure 1. Flow diagram of the patients enrolled into the study (patients randomised to the physical exercise 
program or to standard care) 
 
 
 
3.1 Correlation analyses 
Baseline 6MWT, expressed as number of meters walked in 6 minutes, significantly 
correlated with age (ρ= -0.57, P<0.001), gender (ρ= 0.21, P=0.001), cardiovascular 
comorbidities (ρ= -0.24, P<0.001), diabetes (ρ= -0.20, P=0.001), diastolic blood pressure 
(ρ= 0.38, P<0.001) albumin (ρ= 0.22, P=0.001), phosphate (ρ= 0.22, P<0.001), CRP levels 
(ρ= -0.16, P=0.03) and NYHA class (ρ= -0.21, P<0.001). In a multiple linear regression 
analysis including all univariate correlates of 6MWT, only age (beta= -0.55), gender 
(beta= 0.16), and cardiovascular comorbidities (beta= -0.17) maintained an 
independent association with 6MWT (P<0.02). 
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3.2 Survival analyses 
The median follow-up was 3.3 years (interquartile range: 2.7-3.5 years). During this 
period, 69 patients died, 90 had fatal or non-fatal cardiovascular events, 159 were 
hospitalized. Overall, 182 patients had the composite end-point death/cardiovascular 
events/hospitalizations. In a bivariate Cox regression model, including the allocation 
arm as covariate, an increase of 20 meters walked during the 6MWT significantly 
(P<0.001) reduced the risk of the composite end-point by 6%. Similar results were 
obtained in bivariate analyses of the individual end-points. In these models, an increase 
of 20 meters significantly reduced all-cause death by 12% (P<0.001), fatal and non-fatal 
cardiovascular events by 7% (P<0.001), and all-cause hospitalizations by 4% (P=0.002). 
The relationship between physical performance and the combined end-point was 
confirmed in a model adjusting for age, gender, systolic blood pressure, cholesterol, 
diabetes, smoking, cardiovascular 
comorbidities and allocation arm (HR: 0.94, CI: 0.91-0.98, P=0.001) (Figure 2). By the 
same token, physical performance by 6MWT predicted all-cause death (HR: 0.89, CI: 
0.84-0.94, P<0.001) and hospitalizations (HR: 0.96, CI: 0.92-0.99, P=0.03). A similar 
trend was observed for CV events, but this relationship did not reach statistical 
significance (HR: 0.96, CI: 0.91-1.01, P=0.10). Forcing risk factors peculiar to ESKD 
(haemoglobin, albumin and phosphate) into the model did not modify these 
relationships (Figure 2). 
 
4. DISCUSSION 
This study shows that 6MWT, a test commonly used to measure exercise capacity and 
motor fitness, predicts the risk for mortality, cardiovascular events and hospitalizations 
in chronic kidney disease patients on dialysis. Physical activity, either measured by 
questionnaires (16, 9) or by accelerometers (17) or pedometers (18), is about 50% less 
in dialysis patients than in age and sex matched individuals. In the Dialysis Outcomes 
and Practice Patterns Study (DOPPS), self-reported activity was an independent 
predictor of death and exercising at least once a week predicted a 27% risk reduction 
(19). Similar results emerged from the Wave 2 study of the United States Renal Data 
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System (USRDS) (7) and in a study based on accelerometry (8).While physical activity 
estimates engagement in daily activities, metrics of physical performance provide 
objective measures of motor fitness. As such, metrics of physical performance looking 
at walking speed like Six-Minute Walking Test (6MWT), measure cardiorespiratory 
endurance, muscle endurance and strength as well as balance and coordination.  
The 6MWT has been applied in the whole age spectrum (19, 20) at population level and 
in several conditions, including chronic congestive heart failure (13, 21) and other 
cardiac conditions (22), COPD (14) and in hereditary diseases like cystic fibrosis (20). 
This test has prognostic relevance because it predicts clinical outcomes in several 
categories of patients including elderly patients undergoing coronary artery bypass 
grafting (23) and patients with chronic heart failure treated with cardiac 
resynchronization (24). Whether this test of motor fitness predicts mortality in dialysis 
patients has never been investigated. In this study, we found coherent correlations 
between physical performance (6MWT) and some factors which have an obvious 
influence on health status, such as age, gender, cardiovascular comorbidities, NYHA 
class, diabetes, diastolic blood pressure and other parameters (25-29). However, only 
age, gender and cardiovascular comorbidities maintained an independent association 
with the 6MWT suggesting that these factors are major determinants of motor fitness 
in dialysis patients. According to our working hypothesis that physical performance 
measured by the 6MWT holds prognostic value in dialysis patients, we found that this 
test is a strong predictor of mortality, cardiovascular events and hospitalizations in this 
population. More specifically, in adjusted analyses, we observed a reduction of 6% in 
the combined outcome for each increase of 20 walked meters, and a reduction of 12% 
and 4% for all cause death and hospitalization. Thus our data extend to the dialysis 
population observations made in other conditions (23, 24) and underscore the 
relevance of objective measures of motor fitness in assessing the overall risk profile of 
dialysis patients. Future studies, including phase-2 of EXCITE, will assess whether 
interventions aimed at improving physical fitness may translate into better clinical 
outcomes, including better physical performance, longer survival and reduced rate of 
cardiovascular events and hospitalizations in dialysis patients. 
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Figure 2. Hazard ratio and 95% CI associated to an increase of 20 walked metres during the six-minute walking 
test (6MWT) for the composite end-point (A), all-cause mortality (B), fatal and non-fatal cardiovascular (CV) 
events (C) and hospitalizations (D). 
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Fitness for Entering a Simple 
Exercise Program and Mortality: A 
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Introduction to Enhance 
Performance in Dialysis (EXCITE) 
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ABSTRACT 
Background/Aims: In this corollary analysis of the EXCITE study, we looked at possible 
differences in baseline risk factors and mortality between subjects excluded from the 
trial because non-eligible (n=216) or because eligible but refusing to participate 
(n=116). Methods: Baseline characteristics and mortality data were recorded. Survival 
and independent predictors of mortality were assessed by Kaplan-Meier and Cox 
regression analyses. Results: The incidence rate of mortality was higher in non-eligible 
vs. eligible non-randomized patients (21.0 vs. 10.9 deaths/100 persons-year; P<0.001). 
The crude excess risk of death in noneligible patients (HR 1.96; 95% CI 1.36 to 2.77; 
P<0.001) was reduced after adjustment for risk factors which differed in the two 
cohorts including age, blood pressure, phosphate, CRP, smoking, diabetes, triglycerides, 
cardiovascular comorbidities and history of neoplasia (HR 1.60; 95% CI 1.10 to 2.35; 
P=0.017) and almost nullified after including in the same model also information on 
deambulation impairment (HR 1.16; 95% CI 0.75 to 1.80; P=0.513).  Conclusions: 
Deambulation ability mostly explains the difference in survival rate in non-eligible and 
eligible non-randomized patients in the EXCITE trial. Extending data analyses and 
outcome reporting also to subjects not taking part in a trial may be helpful to assess the 
representability of the study population. 
 
Key Words: Physical exercise, Mortality, Outcome study, Dialysis, Deambulation. 
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1. INTRODUCTION 
Precise definition of the population investigated in clinical trials and in well-planned 
observational studies is fundamental to understand the potential applicability of 
findings in these studies in clinical practice. The CONSORT (Consolidated Standards of 
Reporting Trials) document recommends a specific diagram for describing the flow of 
participants through the main phases of clinical trials (1), from eligibility to actual 
enrollment and follow-up. By the same token, a similar approach has been 
recommended for observational studies by STROBE, another document produced 
under the aegis of the EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research) initiative. The importance of accurate reporting of the selection process of 
subjects enrolled into a trial is of obvious relevance for the generalizability of findings 
in the same trial. However, outcome data in subjects screened but not enrolled in 
clinical trials (as not eligible or as refusing to provide consent to participate) have 
received very little attention and we have been unable to identify even a single study 
focusing on this issue. The problem appears of particular relevance in trials testing 
exercise programs, i.e. trials which selects individuals with an inherently lower risk 
profile, i.e. with a degree of fitness allowing a physical exercise program. We hereby 
report a study corollary to the EXerCise Introduction To Enhance performance in dialysis 
(EXCITE) study, i.e. a multicentric, randomized controlled clinical trial on the 
effectiveness of exercise for improving physical performance and the quality of life and 
for reducing adverse clinical outcomes (mortality, cardiovascular events and 
hospitalizations) in dialysis patients (NCT01255969). We specifically designed this study 
to investigate differences in baseline risk factors and their influence on the overall 
survival in non-eligible patients and in eligible patients who declined the invitation to 
participate into the trial. 
 
2. PATIENTS AND METHODS 
The study protocol was in conformity to the ethical guidelines of our institution and 
informed consent was obtained from each participant. 
 
Chapter 7______________________________________________________________________ 
134 
 
2.1 Patients 
This is a study corollary to the EXerCise Introduction To Enhance performance in dialysis 
(EXCITE) study. More detailed information about this trial are available in 
ClinicalTrials.gov (NCT01255969). In this study we investigated the differences in 
baseline risk factors and their influence on the incidence rate of mortality in non-eligible 
patients (n=216; 90% on HD) and eligible patients who did not give the informed 
consent to take part into the EXCITE trial (n=116; 84% on HD). Deambulation ability was 
categorized as independent, assisted or total inability to deambulate (bedridden or 
wheel-chaired). The main demographic, clinical and biochemical characteristics of 
patients included in this study are given in Table 1.  
 
Table 1. Main demographic, clinical and biochemical characteristics of patients 
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2.2 Laboratory measurements  
Blood sampling was performed during a midweek day (short dialysis interval). Serum 
cholesterol, albumin, calcium, phosphate, C-Reactive Protein (CRP) and haemoglobin 
measurementswere made using standard methods in the routine clinical laboratory. 
Follow up After the initial assessment, the median follow-up was 2.9 years in non-
eligible patients (interquartile range 1.2 to 4.0 years) and 4.0 years in eligible patients 
unwilling to participate into the trial (interquartile range 2.3 to 4.0 years). During follow-
up, death was accurately recorded. Each death was reviewed and assigned an 
underlying cause by a panel of 5 physicians. As a part of the review process, all available 
medical information about each death were collected. This information always included 
study and hospitalisation records. In the case of an out-of-hospital death family 
members were interviewed by telephone to better ascertain the circumstances 
surrounding death.  
 
2.3 Statistical analysis  
Data were expressed as mean ± standard deviation (normally distributed data), median 
and interquartile range (non-normally distributed data) or as per cent frequency 
(categorical data), and the comparisons among groups were made by One Way ANOVA, 
Kruskal-Wallis Test and Chi Square Test, as appropriate. In each study cohort, the 
independent predictors of mortality were identified by Kaplan-Meier survival analysis 
and by univariate and multivariate Cox regression models. Tested variables included 
age, gender, smoking, diabetes, blood pressure, total cholesterol, triglycerides, 
haemoglobin, albumin, calcium, phosphate, C-Reactive Protein, history of neoplasm, 
myocardial infarction, stroke, TIA, angina episodes, arrhythmia, peripheral vascular 
disease, and heart failure. We built-up multiple Cox regression models specific to each 
study cohort, by introducing into these models all variables which were related to all-
cause mortality with P<0.10. To assess whether the observed difference in the death 
risk among the two study cohorts (i.e. non-eligible patients and eligible non-randomized 
patients) could be explained by differences in baseline risk factors (Table 1), we 
performed a multiple Cox regression analysis in the whole study population (n=648) 
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including the group (cohort) variable and a series of risk factors which were related 
(with P<0.10) to mortality in each study cohort (Table 2) and/or differed (with P<0.10) 
among the two cohorts (Table 1). By this strategy we constructed models of adequate 
statistical power (i.e. at least 10 deaths for each variable into the models). In the survival 
analysis, data were expressed as hazard ratio, 95% confidence interval and P value. The 
explained variation in mortality attributable to single variables was calculated by the 
method proposed by Hosmer and Lemeshow (2). Statistical analysis was performed by 
using a standard statistical package (SPSS for Windows, Version 20, Chicago, Illinois, 
USA  
 
3. RESULTS 
The source population of the EXCITE study included 648 patients with ESKD. Among 
these, 216 patients were excluded because they did not meet inclusion criteria (33%), 
116 patients were eligible but did not give the informed consent (18%) and the 
remaining 316 patients were randomized (49%). Most non-eligible patients (64%) did 
not deambulate autonomously and/or needed to be assisted in everyday life. Eligible 
patients nonparticipating into the study were significantly younger and displayed a 
lower proportion of patients with angina, arrhythmia, heart failure and TIA as compared 
to non-eligible patients. Circulating levels of phosphate and the prevalence of smokers 
and hypertensive patients were higher in eligible non-randomized patients than in non-
eligible patients (Table 1). Circulating levels of C-Reactive Protein (CRP) and the 
prevalence of peripheral vascular disease were higher in non-eligible patients than in 
eligible patients who did not give the informed consent (Table 1).  
 
3.1 Predictors of mortality in eligible non-randomized patients and in ineligible 
patients  
During the follow-up period, the number of deaths was 119 in non-eligible patients 
(55%) and 41 in eligible non-randomized (35%) patients. In non-eligible patients, age, 
triglycerides, phosphate, CRP, history of heart failure, history of peripheral vascular 
disease and deambulation degree (autonome, assisted or bedridden/wheelchaired) 
_____________________________Fitness for entering a simple exercise program and mortality 
137 
 
predicted death with formal statistical significance (p<0.05) while only age, history of 
arrhythmia and history of neoplasia associated significantly with the same outcome in 
eligible patients who did not enter into the trial (Table 2). Non-significant associations 
(p>0.05, p<0.10) with death were noted for smoking (Table 2). In multivariate analyses 
mortality was predicted only by age, triglycerides, CRP, degree of deambulation and 
history of heart failure in non-eligible patients (Table 3a) and only by age in eligible non-
randomized patients (Table 3b).  
 
3.2 Comparison of survival in eligible non-randomized patients and in ineligible 
patients  
The incidence rate of mortality was substantially higher in non-eligible patients 
(incidence rate: 21.0 deaths/100 persons-year) than in eligible non-randomized 
patients (incidence rate: 10.9 deaths/100 persons-year) (Log rank test: χ2=13.85, p 
<0.001) (Figure 1a). To assess whether the difference in baseline risk factors could 
explain the difference in the death risk of the two study cohorts, we performed two 
multivariate analyses including the group variable of eligible and non-eligible patients 
(cohorts) and a series of risk factors which were related to mortality (with p<0.10) in 
each study cohort (Table 2) and/or differed (with p<0.10) among the two cohorts (Table 
1). To estimate the impact of the degree of deambulation impairment on mortality we 
tested two models, the first excluding deambulation ability and the second including 
this co-variate. In the first model the crude difference in the mortality risk among the 
two cohorts (HR 1.96; 95% CI 1.36 to 2.77; P<0.001) was reduced modestly (HR 1.60; 
95% CI 1.10 to 2.35; P=0.017) (Figure 1b and Table 4). However, additional adjustement 
for deambulation almost nullified the excess risk of death seen in non-eligible patients 
(HR 1.16; 95% CI 0.75 to 1.80; P=0.513) (Figure 1c and Table 4). Of note, the explained 
variation in all-cause mortality was 33% for the model excluding and 38% for the model 
including the deambulation variable (P<0.0005). Thus, deambulation captures as much 
as the 13% in the explained variability in the risk of death.  
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Table 2. Univariate Cox regression analyses in the two study cohorts. Categories grading deambulation 
impairment are listed in Table 1 
 
 
 
Table 3. Cox regression in non-eligible patients (a) and eligible non- randomized patients (b) 
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Table 4. Multivariate Cox regression analysis in the whole study population 
 
 
Figure 1. Unadjusted and adjusted survival analyses in the two study groups (non-eligible and eligible non 
randomized patients) 
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4. DISCUSSION 
This study corollary to a multicenter randomized, clinical trial testing the effect of 
physical exercise in dialysis patients shows that the mortality risk is twice higher in 
patients who were excluded from the trial than in eligible patients who did not accept 
to participate. Importantly, the mortality rate in this group (10.9 deaths/100 persons-
year) was lower than the average mortality rate in the ERA-EDTA registry (3) and in the 
Italian registry of dialysis (4). As expected, the two populations which remained external 
to the trial, i.e. the ineligible population and the population with sufficient fitness but 
unwilling to undergo the exercise program, showed several differences in baseline risk 
factors such as age, blood pressure, phosphate, CRP, smoking, diabetes, triglycerides, 
cardiovascular comorbidities and history of neoplasia. We hypothesized that these 
differences could explain the higher death risk of ineligible patients and tested this 
hypothesis by modeling death risk in an analysis where the two cohorts were nominally 
identified by a specific covariate. The proviso was that the inclusion of known risk 
factors differentiating the two cohorts should attenuate substantially or cancel out the 
excess death risk of unfit patients ineligible to the trial. However, in contrast to our 
working hypothesis, we found that adjustment for background risk factors only in 
limited part explained the between cohorts difference in mortality. This finding 
indicates that major risk factors fail to fully capture the higher probability of death in 
patients ineligible to clinical studies. Thus, the higher death rate in those patients must 
necessarily depend on unmeasured risk factors of paramount importance for human 
health. Most non-eligible patients (64%) did not deambulate autonomously or needed 
to be assisted, indicating that comorbidities limiting motor activity in everyday life mark 
a degree of severity that is unaccounted for by nominally defined, ungraded, major 
comorbidities like arrhythmia, heart failure, cerebro- and peripheral-vascular disease, 
ischemic heart disease and neoplasia. Indeed, when we introduced into the model 
deambulation impairment, the between cohorts difference in the risk of death almost 
disappeared (HR 1.16; 95% CI 0.75to 1.80; P=0.513). This observation is of importance 
because physical performance and inability to deambulate are very rarely taken into 
account when describing the risk profile of dialysis patients in major clinical trials and 
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observational studies in this population. For example, neither in the 4D (5), nor in the 
AURORA study (6), nor in the more recent EVOLVE trial (7), physical disability was an 
exclusion criterion but in none of these trials information on physical disability was 
given. About 1/3 (33%) of the source cohort of the EXCITE study had a relevant degree 
of physical impairment and it is likely that a similar proportion existed in the source 
populations of other trials in dialysis patients. The variability in mortality rate explained 
by unfitness to a simple exercise program is substantial and ignoring severe limitation 
in physical functioning may have a non-trivial effect for the interpretation of the risk 
profile of patients included in clinical studies. However, as discussed, information on 
ambulatory ability is almost always omitted in trials in the dialysis population. Findings 
in this study represent a call for systematic reporting information on physical activity 
and/or (motor) ability in clinical trials and observational studies in this population. 
Indeed –well beyond classical risk factors, background co-morbidities and risk factors 
peculiar to end-stage renal disease- deambulation impairment explains a relevant 
proportion of the variability in mortality in ESKD. Furthermore, our findings suggest that 
extending outcome reporting and data analyses to the whole source population of 
clinical trials may provide relevant information to better frame the implications of the 
selection process applied to restrict the trial population to patients with well-defined 
demographic and clinical characteristics. 
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The studies included in this thesis provide new insights on the clinical impact of aging, 
physical activity and emerging risk factors in individuals with impaired renal function. 
In particular, I have found that pulmonary hypertension (PH), which is in most cases 
clinically unsuspected, may represent an important missing piece for improving 
cardiovascular risk stratification, even in those individuals with no evidence of lung or 
heart disease. PH is highly prevalent in CKD patients, particularly in individuals on 
chronic replacement therapy by hemodialysis. Apart from the presence of other co-
morbidities or systemic diseases, several CKD-specific risk factors including the 
presence of artero-venous fistula, fluid overload, sleep breathing disorders and the 
exposure to dialysis membranes can be implicated at various levels in increasing 
pulmonary pressure. PH in CKD is a potentially reversible process because it may regress 
after kidney transplantation. However, the excess mortality conveyed by this condition 
may persist in some kidney graft recipients.  
My work also accrued evidence pointing at aging as a key-determinant of major 
alterations in kidney biology. Although distinguishing normal renal senescence from 
pathological chronic kidney disease is, in most cases, far from being simple, a systematic 
and correct estimation of renal function in the elderly and the establishment of proper 
therapeutic measures in a timely manner appear of foremost importance for improving 
clinical outcomes in this particular population setting.  In parallel to renal function, 
aging may also affect fitness capacity. Early changes of vascular responses to exercise 
prior to a clear reduced physical activity may eventually end in a severely impaired 
mobility. This latter trend is of importance, particularly for patients on chronic dialysis. 
In fact, I found that, in these individuals, a reduced exercise capacity or (even more 
clearly) an impaired mobility, may convey an incremental risk of worse outcomes. This 
suggests that appropriate and “tailored” fitness approaches in patients on dialysis may 
bring remarkable benefits as previously observed in other frail populations. 
 
Influence of aging on renal biology and functionality 
The dramatic population aging on a world scale may anticipate a burden of elderly 
individuals with end-stage kidney disease who are expected to significantly impact 
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health care resources. For instance, according to the US Renal Data System, during 
2005–2013, the adjusted point prevalence rates per million population of reported end-
stage renal disease increased from 70.5 to 82.1 (16% increase) in the age group 0–19 
years, from 730.6 to 858.2 (17% increase) in the age group 20–44 years, from 2333.3 to 
3150.4 (35% increase) in the age group 45–64 years, from 3627.5 to 5500.6 (51% 
increase) in the age group 65–74 years, and from 2762.4 to 4795.8 (73% increase) in 
the age group 75+ years (2). Time projections over the next 20 years seem to reinforce 
the concept that old and very old individuals will account for more than 50% of incident 
and prevalent ESKD cases worldwide. It is therefore not surprising that, in last years, 
the aging kidney has become a topic of great interest in geriatric medicine and clinical 
nephrology (1).  
Through a systematic approach to the existing literature, I found collective evidence 
indicating that renal aging is a multifactorial process where gender, race and genetic 
background and several key-mediators such as oxidative stress, the renin-angiotensin-
aldosterone (RAAS) system, impairment in kidney repair capacities and background 
cardiovascular disease, play a significant role. Features of the aging kidney include 
macroscopic and microscopic changes and key functional adaptations. Unfortunately, 
none of these can be considered pathognomonic of aging. Hence, the question to which 
extent renal aging should be considered as a physiological or pathological process 
remains mostly unanswered. Effective strategies for retarding kidney aging or for 
limiting its detrimental effects on pre-existing age-related kidney diseases might be 
essential for limiting the above-mentioned, dramatic CKD scenario. Yet, although 
promising dietary and pharmacological approaches have been tested to retard aging 
processes or renal function decline in the elderly, proper lifestyle modifications, as 
those applicable to the general population, currently represent the most plausible 
approach to maintain kidney health. 
Improved understanding of renal aging might, in theory, also help optimizing the 
management of renal allografts obtained from older donors. For instance, it has been 
suggested that the early occurrence of critical telomere shortening and replicative 
senescence may contribute to the pathogenesis of chronic allograft nephropathy in 
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older allografts (3). Hence, efforts to understand the age-related changes in kidney 
function and mechanisms, which underlie these changes, might help identifying 
potential interventions for maximizing successful donations from the so-called 
“marginal” kidneys. 
 
Role of pulmonary pressure as a new risk factor in renal patients 
Although patients with chronic kidney disease consume an unequal share of health care 
resources, mortality and cardiovascular morbidity remain unacceptably high, 
particularly in persons with End-Stage Kidney Disease (4). Such a risk excess remains 
partly unexplained. The majority of interventions targeting traditional or “uremia-
related” risk factors failed to significantly improve event-free survival. New prognostic 
indicators are therefore needed to refine outcome prediction and drive therapeutic 
management in this population. By approaching the existing literature in a systematic 
way, I found that mild-to-moderate forms of pulmonary hypertension (PH) have high 
prevalence among renal patients. Of note, in some hemodialysis population, such 
prevalence was reported to be as high as 70%. Even if clinically unsuspected, the 
presence of PH must deserve attention in this particular disease category. In fact, in an 
ample cohort of individuals with non-advanced CKD, I found that PH was a strong 
predictor of a combined endpoint including cardiovascular death, acute heart failure, 
coronary artery disease, cerebrovascular and peripheral artery events. Of note, PH 
remained an independent risk factor also in analyses adjusting for a series of potential 
confounders including age, residual renal function, haemoglobin, cardiac volumes and 
mass, presence of diabetes and prior CV disease. In the general population, over the 
last ten years, an increasing trend in mortality due to PH was documented with an 
estimated age-adjusted death rate of 4.5 to 12.3 per 100.000 (5). Of note, even in large 
cohorts of individuals with moderate to severe heart disease, the predictive power of 
PH remains independent from traditional cardiovascular risk factors and parameters of 
(left) heart dysfunction (6). Hence, in renal patients, PH may convey an incremental 
mortality and cardiovascular risk that reflects that evidenced at the community level 
and in other “high risk” populations. The question whether PH is a modifiable risk factor 
_____________________________________________________________________Discussion 
147 
 
in CKD patients should be addressed by targeted clinical trials. However, some issues 
may hinder future research in this field. 
As indicated by current guidelines on PH management (7), right heart catheterization is 
essential for confirming the diagnosis and characterizing the disease. Yet, the vast 
majority of studies on PH in CKD used estimated (ePAP) rather than measured (mPAP) 
pulmonary artery pressure values to identify this condition. Although ePAP is 
considered a valid surrogate of mPAP, particularly for screening purposes, estimated 
values may significantly diverge from real measures and do not allow disease 
categorization (8). This aspect could represent a serious limit for establishing proper 
therapeutic approaches to treat PH in renal patients. In the general population, 
treatments aiming at optimizing left ventricular function and alleviating fluid overload 
(e.g. diuretics, beta blockers, drugs influencing the renin-angiotensin-aldosterone 
(RAAS) system) are fundamental for normalizing PH secondary to congestive heart 
failure (9,10). Conversely, the use of vasoactive agents is usually confined to patients 
with primary pulmonary arterial hypertension. Since left ventricular disorders are highly 
prevalent in the CKD population, the recommendations for the treatment of PH WHO 
II category (that is secondary to heart disease) in the general population (9) could 
reasonably apply also to this disease setting. Yet, no solid evidence on the treatment of 
PH in patients with CKD is available so far (10). Hence, drug therapies, whereas 
necessary, should be considered on the basis of the individual risk-benefit profile as 
most drugs may be harmful in the presence of severe renal impairment (11). In view of 
this “grey area” of evidence, future research including large scale, interventional studies 
adopting well standardized criteria of PAP measurement, such as right heart 
catheterization, would be of utmost importance to confirm the need for clinical 
attention on PH and to define benefits and harms of appropriate therapeutic 
approaches also in the CKD setting. 
 
Aging, response to exercise and clinical impact of physical activity in dialysis patients 
Failure of the arterial system during stress and increased vascular resistance are well-
known hallmarks of the senescence process (12). Vascular ageing results in loss of 
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elastic properties, which triggers an increase in systolic pressure and a decrease in 
diastolic pressure due to progressive stiffness of the large elastic arteries (12). This may 
result in damage to small arterial vessels of the coronary, brain and kidney vascular 
districts, hence accelerating chronic cardiovascular or renal disease. No less important, 
poor vascular compliance to physical efforts elicits a reduced muscle tolerance to daily-
life activities that accounts for most of the sedentary habits which characterizes old 
individuals. Similar to the elderly population, hemodialysis individuals are also 
characterized by a moderate-to-severely reduced physical activity (13). The increasing 
need for hemodialysis in our growing elderly populations will reduce the quality of live 
with more co-morbidities including depression (14). National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative Guidelines formally recommend dialysis patients to 
be “counseled and regularly encouraged by nephrology and dialysis staff to increase 
their level of physical activity” (15). However, the evidence for recommending exercise 
training in this setting is still limited. With the EXCITE study (Exercise Introduction to 
Enhance Performance in Dialysis), a randomized, multicenter trial of moderate walking 
exercise to improve functional status in ESKD individuals, I demonstrated that reduced 
walking capacity predicts a high risk of mortality, cardiovascular events and 
hospitalizations in dialysis patients. The walking capacity encompasses 
cardiorespiratory and muscle endurance, muscle strength and balance and 
coordination, which are fundamental in daily living in patients with chronic kidney 
disease and in the elderly (16). Very importantly, similar observations were previously 
made in other frail, high-risk populations, such as elderly patients undergoing coronary 
artery bypass grafting (17) and patients with chronic heart failure treated with cardiac 
resynchronization (18). Hence, our findings extend the relevance of objective measures 
of motor fitness in assessing the overall risk profile to the dialysis population. Starting 
from these premises, future studies are required to assess whether improving motor 
fitness translates into better clinical outcomes in the dialysis population. 
Of similar importance, in another analysis of the same trial, I also demonstrated that 
mobility mostly explains the difference in survival rate in non-eligible and eligible non-
randomized patients. In other words, despite the two groups that remained outside the 
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trial (i.e. the ineligible population and the population with sufficient fitness but 
unwilling to undergo the exercise program) had several differences in baseline risk 
factors, adjustment for these background risk factors explained little mortality 
compared to the large effect of impaired mobility. This is important for at least two 
reasons. First it underlines the need for a systematic reporting information on physical 
activity and/or (motor) ability in clinical trials and observational studies conducted in 
dialysis patients. Second, and more general, it confirms that extending data analyses 
and outcome reporting also to subjects not taking part in a trial may be helpful to assess 
the representability of the study population. 
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Summary 
The number of elderly persons worldwide is forecasted to grow dramatically over the 
next decades. Hence, future medicine will inevitably face new challenges related to the 
several, inexorable consequences of aging. The assessment of renal function in the 
framework of aging is problematic and the question whether renal aging should be 
considered as a physiological or pathological process remains an open issue. Gender, 
race, genetic background and other mediators such as oxidative stress, the renin-
angiotensin-aldosterone (RAAS) system, impairment of kidney repair capacities and 
background cardiovascular disease, are all key-players of kidney aging. Whether or not 
promising dietary and pharmacological approaches targeting some of these factors 
retard renal senescence and prevent chronic kidney disease (CKD) is currently tested. 
Indeed, there is an urgent need to identify new prognostic biomarkers for refining 
outcome prediction in CKD individuals. Pulmonary hypertension (PH), a powerful and 
independent predictor of death in the general population and in subjects with heart or 
lung diseases, is highly prevalent also in renal patients and may hold the same 
prognostic utility for risk stratification and therapeutic management, particularly in 
persons with early CKD stages.  As for the kidney and other organs, senescence is known 
to impair also physical capacity. In a pilot trial of healthy individuals of various ages, I 
found increased blood pressure levels after isometric challenge and a strong association 
between handgrip strength and change in blood pressure levels and aortic stiffness in 
elderly subjects. This altered vascular hemodynamics may reflect vascular ageing, a 
prelude to a decline in physical activity and mobility which characterizes the majority 
of old individuals. Similar to the elderly population, hemodialysis individuals have also 
a reduced physical activity. In an analysis of the EXCITE (Exercise Introduction to 
Enhance Performance in Dialysis) trial, a significantly reduced walking capacity 
predicted a high risk of mortality, cardiovascular events and hospitalizations in dialysis 
patients; this substantiates the importance of including objective measures of motor 
fitness in assessing the overall risk profile of dialysis and elderly study populations. In 
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another analysis of the same study, I focused on two groups, who remained outside the 
trial. Despite several differences in baseline risk factors, an impaired mobility was the 
sole variable clearly explaining the difference in survival rate between these two sub-
populations. Future studies are required to assess whether improving fitness may 
translate into better clinical outcomes in this high risk population. 
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Samenvatting 
 
Verwacht wordt dat het aantal ouderen wereldwijd de komende decennia dramatisch 
zal groeien. Daarom zal de toekomstige geneeskunde onvermijdelijk geconfronteerd 
worden met nieuwe uitdagingen met betrekking tot de verschillende, onverbiddelijke 
gevolgen van veroudering. De beoordeling van de nierfunctie in het kader van het ouder 
worden is problematisch en de vraag of nierveroudering moet worden beschouwd als 
een fysiologisch of pathologisch proces, blijft een open vraag. Geslacht, ras, genetische 
achtergrond en andere mediatoren zoals oxidatieve stress, het renine-angiotensine-
aldosteron (RAAS) -systeem, verminderde niercapaciteit en cardiovasculaire 
aandoeningen zijn spelers van nierveroudering. Of op dit moment veelbelovende 
voedings- en farmacologische benaderingen die op sommige van deze factoren zijn 
gericht, de renale senescentie vertragen en chronische nieraandoeningen (CKD) 
voorkomen, worden momenteel getest. Er is zeker een dringende behoefte aan het 
identificeren van nieuwe prognostische biomarkers voor het verfijnen van de 
voorspelde uitkomst bij CKD-individuen. Pulmonale hypertensie (PH), een krachtige en 
onafhankelijke voorspeller van overlijden in de algemene bevolking en bij personen met 
hart- of longaandoeningen, komt ook veel voor bij nierpatiënten en kan hetzelfde 
prognostische nut hebben voor risicostratificatie en therapeutisch management, met 
name bij personen met vroege CKD-stadia. Wat de nier en andere organen betreft, is 
bekend dat senescentie ook de fysieke capaciteit schaadt. In een pilot-onderzoek met 
gezonde individuen van verschillende leeftijden, vond ik verhoogde bloeddrukniveaus 
na isometrische uitdaging en een sterke associatie tussen handgreepsterkte en 
verandering in bloeddrukniveaus en aortastijfheid bij oudere proefpersonen. Deze 
veranderde vasculaire hemodynamica kan vaatveroudering weerspiegelen, een 
opmaat naar een afname in fysieke activiteit en mobiliteit die kenmerkend is voor de 
meerderheid van de oude personen. Net als oudere patiënten hebben hemodialyse-
individuen ook een verminderde fysieke activiteit. In een analyse van de EXCITE-test 
(Exercise Introduction to Enhance Performance in Dialysis), voorspelde een significant 
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verminderde loopcapaciteit een hoog risico op mortaliteit, cardiovasculaire 
gebeurtenissen en ziekenhuisopnames bij dialysepatiënten; dit onderbouwt het belang 
van het opnemen van objectieve metingen van motorische fitheid bij het beoordelen 
van het algehele risicoprofiel van dialyse en oudere studiepopulaties. Ondanks 
meerdere verschillen in basislijnrisicofactoren, was een verminderde mobiliteit de 
enige variabele die het verschil in overlevingspercentage tussen deze twee 
subpopulaties duidelijk verklaarde. Toekomstige studies zijn nodig om te beoordelen of 
het verbeteren van conditie kan leiden tot betere klinische uitkomsten in hoog risico 
deze populatie. 
 
 
 
 
 
  
_________________________________________________________________PhD PORTFOLIO 
155 
 
PHD PORTFOLIO        
Name PhD student:  
Davide Bolignano 
Period: 2015-2018 
Erasmus MC Department:  
Internal Medicine 
Promotors:    Prof. F.U.S. Mattace-Raso,  
                         Prof. E.J.G. Sijbrands 
Research School: COEUR Co-promotor: Dr.G. Tripepi 
 
PhD Training: 
Research skills 
- Aging and cardiovascular risk factors in kidney diseases 
- Exercise in dialysis patients 
- Systematic reviews and meta-analyses 
 
Invited Lectures 
- Rare Disease? Challenging guideline. European Renal Best Practice CME Course at 
the 52nd ERA-EDTA Congress. London, May 2015 
- Pulmonary hypertension in CKD patients: Relevant? Preventable? Treatable? 53rd 
ERA-EDTA Congress, Vienna, May 2016.  
- Dialysis modality choice in diabetic patients with end-stage kidney disease. 53rd 
ERA-EDTA Congress, Vienna, May 2016. 
- Clinical Guidance in Rare Kidney Diseases: Time to Revisiting Research 
Methodology? 24th Budapest Nephrology School, Budapest, August 2017 
- The Conundrum of First Dialysis Modality in Diabetic Patients with ESKD. 24th 
Budapest Nephrology School, Budapest, August 2017 
- Stealing my heart: Vascular Access and Pulmonary Hypertension. 50th ASN Kidney 
Week, New Orleans (US), November 2017 
- Facing obesity in kidney transplantation. European Renal Best Practice CME Course 
at the 55th ERA-EDTA Congress, Copenhagen, Denmark, May 23 2018. 
 
PhD PORTFOLIO_________________________________________________________________ 
156 
 
International Conferences 
- 52nd ERA-EDTA Congress. London 2015 
- 53rd ERA-EDTA Congress. Vienna 2016 
- 54th ERA-EDTA Congress. Madrid 2017 
- 24th Budapest Nephrology School. Budapest 2017 
- 50th ASN Kidney Week. New Orleans (US) 2017 
- 9th European Conference on Rare Diseases and Orphan Products, Vienna, 2018 
- 55th ERA-EDTA Congress. Copenhagen, 2018 
 
Other 
- Editor in Chief of NDT-Educational 
- Academic Editor of PLOS One 
- Editorial Board member for Journal of Onco-Nephrology and Journal of Renal and 
Hepatic Disorders 
- Reviewer for: Journal of the American Society of Nephrology, PLOS one, 
Nephrology Dialysis and Transplantation, Clinical Chemistry and Laboratory 
Medicine, Nature Reviews Nephrology, Critical Care, Kidney International, Clinical 
Journal of the American Society of Nephrology, American Journal of Nephrology, 
JAMA, Biomarkers in Medicine, International Urology and Nephrology, Journal of 
Nephrology, Clinical Kidney Journal, Future Medicine, World Journal of 
Gastroenterology, Trials, Clinical Pharmacokinetics, Obesity Research & Clinical 
Practice, Annals of Medical and Health Sciences Research, BMC Nephrology, Expert 
Review of Clinical Pharmacology, Endocrine. 
 
  
___________________________________________________________LIST OF PUBLICATIONS 
157 
 
LIST OF ALL PUBLICATIONS (2015-2018) 
1. Bolignano D, Pisano A, Coppolino G, Tripepi GL, D'Arrigo G. Pulmonary 
hypertension predicts adverse outcomes in renal patients: a systematic review 
and Meta-Analysis. Ther Apher Dial. 2018 Nov 22. doi: 10.1111/1744-
9987.12777 
2. Pisano A, D’Arrigo G, Coppolino G, Bolignano D. Biotic Supplements for Renal 
Patients: A Systematic Review and Meta-Analysis. Nutrients. 2018, 10, 1224. 
3. Grassi G, Pisano A, Bolignano D, Seravalle G, D'Arrigo G, Quarti-Trevano F, 
Mallamaci F, Zoccali C, Mancia G. Sympathetic Nerve Traffic Activation in 
Essential Hypertension and Its Correlates: Systematic Reviews and Meta-
Analyses. Hypertension. 2018 Jun 18 
4. Coppolino G, Bolignano D, Gareri P, Ruberto C, Andreucci M, Ruotolo G, Rocca 
M, Castagna A. Kidney function and cognitive decline in frail elderly: two faces 
of the same coin? Int Urol Nephrol. 2018 Jun 4 
5. Hartog R, Bolignano D, Sijbrands E, Pucci G, Mattace-Raso F. Short term 
vascular hemodynamic responses to isometric exercise in young adults and in 
the elderly. Clin Interv Aging 2018:13 509–514 
6. Abd ElHafeez S, Bolignano D, D'Arrigo G, Dounousi E, Tripepi G, Zoccali C. 
Prevalence and burden of chronic kidney disease among the general 
population and high-risk groups in Africa: a systematic review. BMJ Open. 2018 
Jan 10;8(1):e015069 
7. Coppolino G, Leporini C, Rivoli L, Ursini F, di Paola ED, Cernaro V, Arturi F, 
Bolignano D, Russo E, De Sarro G, Andreucci M. Exploring the effects of DPP-4 
inhibitors on the kidney from the bench to clinical trials. Pharmacol Res. 2017 
Dec 6 
8. Nistor I, De Sutter J, Drechsler C, Goldsmith D, Soler MJ, Tomson C, Wiecek A, 
Donciu MD, Bolignano D, Van Biesen W, Covic A. Effect of renin-angiotensin-
aldosterone system blockade in adults with diabetes mellitus and advanced 
chronic kidney disease not on dialysis: a systematic review and meta-analysis. 
Nephrol Dial Transplant. 2017 Jul 2. 
9. Pisano A, Cernaro V, Gembillo G, D'Arrigo G, Buemi M, Bolignano D. Xanthine 
Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease 
Patients: An Updated Systematic Review and Meta-Analysis. Int J Mol Sci. 2017 
Oct 31;18(11). 
10. Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, 
Bolignano D, Zoccali C, Blankestijn PJ. Renal safety of catheter-based renal 
denervation: systematic review and meta-analysis. Nephrol Dial Transplant. 
2017 Sep 1;32(9):1440-1447. 
LIST OF PUBLICATIONS___________________________________________________________ 
158 
 
11. Coppolino G, Cernaro V, Placida G, Leonardi G, Basile G, Bolignano D. 
Endothelial progenitor cells at the interface of chronic kidney disease: from 
biology to therapeutic advancement. Curr Med Chem. 2017 Sep 20. 
12. Bolignano D, Cernaro V, Gembillo G, Baggetta R, Buemi M, D’Arrigo G. 
Antioxidant agents for delaying diabetic kidney disease progression: a 
systematic review and meta-analysis. PLoS One. 2017 Jun 1;12(6):e0178699 
13. Bolignano D, Coppolino G. Cochrane corner: renal denervation for resistant 
hypertension-a broken promise? Heart. 2017 May 13 
14. Bolignano D, Zoccali C. Non-proteinuric rather than proteinuric renal diseases 
are the leading cause of end-stage kidney disease. Nephrol Dial Transplant. 
2017 Apr 1;32(suppl_2):ii194-ii199 
15. Coppolino G, Pisano A, Rivoli L, Bolignano D. Renal Denervation for Resistant 
Hypertension. Cochrane Database of Systematic Reviews. 2017 Feb 
21;2:CD011499 
16. Bolignano D, Zoccali C. The PATHWAY-2 study. G Ital Cardiol (Rome). 2016 
Dec;17(12):951-953 
17. Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, 
Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. 
Gitelman syndrome: consensus and guidance from a Kidney Disease: 
Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 
2017 Jan;91(1):24-33 
18. D’Arrigo G, Baggetta R, Tripepi G, Galli G, Bolignano D. Effects of vitamin E-
coated versus conventional membranes in chronic haemodialysis patients: a 
systematic review and meta-analysis. Blood Purif 2016 Dec 14;43(1-3):101-122 
19. Manfredini F, Mallamaci F, D'Arrigo G, Baggetta R, Bolignano D, Torino C, 
Lamberti N, Bertoli S, Ciurlino D, Rocca-Rey L, Barillà A, Battaglia Y, Rapanà RM, 
Zuccalà A, Bonanno G, Fatuzzo P, Rapisarda F, Rastelli S, Fabrizi F, Messa P, De 
Paola L, Lombardi L, Cupisti A, Fuiano G, Lucisano G, Summaria C, Felisatti M, 
Pozzato E, Malagoni AM, Castellino P, Aucella F, ElHafeez SA, Provenzano PF, 
Tripepi G, Catizone L, Zoccali C. Exercise in Patients on Dialysis: A Multicenter, 
Randomized Clinical Trial. J Am Soc Nephrol. 2017 Apr;28(4):1259-1268 
20. Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, Tripepi G, 
D’Arrigo G, Gesualdo L. Renal biopsy in diabetic patients: a pooled meta-
analysis of 48 studies. Nephrol Dial Transplant. 2017 Jan 1;32(1):97-110 
21. Zoccali C, Torino C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, 
Bolignano D, Cutrupi S, Ghiadoni L, Thadhani R, Tripepi G, Mallamaci F. Serum 
phosphate modifies the vascular response to vitamin D receptor activation in 
___________________________________________________________LIST OF PUBLICATIONS 
159 
 
chronic kidney disease (CKD) patients. Nutr Metab Cardiovasc Dis. 2016 
Jul;26(7):581-9 
22. Leporini C, Pisano A, Russo E, D’Arrigo G, De Sarro GB, Coppolino G, Bolignano 
D. Effect of Pentoxifylline on renal outcomes in chronic kidney disease 
patients: a systematic review and meta-analysis. Pharmacol Res. Pharmacol 
Res. 2016 Mar 17;107:315-332 
23. van der Veer SN, van Biesen W, Bernaert P, Bolignano D, Brown EA, Covic A, 
Farrington K, Jager KJ, Kooman J, Macías-Núñez JF, Mooney A, van Munster 
BC, Topinkova E, Van Den Noortgate NJ, Wirnsberger G, Michel JP, Nistor I. 
Priority topics for European multidisciplinary guidelines on the management 
of chronic kidney disease in older adults. Int Urol Nephrol. 2016 Jun;48(6):859-
69 
24. Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, Tripepi G, 
D’Arrigo G, Gesualdo L. Renal biopsy in 2015- from epidemiology to evidence-
based indications. Am J Nephrol 2016 Feb 5;43(1):1-19 
25. Bolignano D, Pisano A. Good quality research in rare diseases: trials and 
tribulations. Ped Nephrol 2016 Nov;31(11):2017-23 
26. Nacak H, Bolignano D, Van Diepen M, Dekker F, Van Biesen W. Timing of start 
of dialysis in diabetes mellitus patients: a systematic literature review. Nephrol 
Dial Transplant. 2016 Feb;31(2):306-16 
27. Nistor I, Bolignano D, Haller MC, Nagler E, van der Veer SN, Jager K, Covic A, 
Webster A, Van Biesen W. Why creating standardized core outcome sets for 
chronic kidney disease will improve clinical practice. Nephrol Dial Transplant. 
2015 Oct 23. pii: gfv365 
28. Bolignano D, D’Arrigo G, Pisano A, Coppolino G. Pentoxifylline for anemia in 
chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2015 
Aug 3;10(8):e0134104 
29. Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig J, Strippoli GFM. 
Interventions for preventing the progression of autosomal polycystic kidney 
disease. Cochrane Database of Systematic Reviews. 2015. Jul 14;7:CD010294 
30. Bolignano D, Pisano A, Coppolino G. The Dark Side of blocking RAS in diabetic 
patients with incipient or manifested nephropathy. Exp Clin Endocrinol 
Diabetes. 2016 Jun;124(6):350-60 
31. Zoccali C, Bolignano D, D’Arrigo G, Dekker FW, Fliser D, Heine GH, Jager KJ, 
Kanbay M, Mallamaci F, Massy Z, Ortiz A, Parati G, Rossignol P, Tripepi G, 
Vanholder R, Wiecek A, London G. Validity of vascular calcification as a 
screening tool and as a surrogate end-point in clinical research. Hypertension. 
2015 Jul;66(1):3-9 
LIST OF PUBLICATIONS___________________________________________________________ 
160 
 
32. Guideline development group. Clinical Practice Guideline on management of 
patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 
mL/min). Nephrol Dial Transplant. 2015 May;30 Suppl 2:ii1-ii142. 
33. Basile C, Pisano A, Lisi P, Rossi L, Lomonte C, Bolignano D. High versus low 
dialysate sodium concentration in chronic haemodialysis patients: a 
systematic review of 23 studies. Nephrol Dial Transplant 2016 Apr;31(4):548-
63 
34. Bolignano D, Lennartz S, Leonardis D, D’Arrigo G, Tripepi R, Emrich IE, 
Mallamaci F, Fliser D, Heine G, Zoccali C. High estimated pulmonary artery 
systolic pressure predicts cardiovascular outcomes in stage 2-4 chronic kidney 
disease. Kidney Int 2015. Jul;88(1):130-6 
35. Coentrão L, Van Biesen W, Nistor I, Tordoir J, Gallieni M, Monros AM, 
Bolignano D. Preferred haemodialysis vascular access for diabetic chronic 
kidney disease patients: a systematic literature review. J Vasc Access 2015, Jul-
Aug;16(4):259-64 
36. Aucella F, Battaglia Y, Bellizzi V, Bolignano D, Capitanini A, Cupisti A. Physical 
excercise programs in CKD: lights, shades and perspectives. A position paper 
of the “Physical Exercise in CKD Study Group“ of the Italian Society of 
Nephrology. J Nephrol 2015 Apr;28(2):143-50  
37. Couchoud C, Bolignano D, Nistor I, Jager KJ, Heaf J, Heimburger O, Van Biesen 
W; on Behalf of the European Renal Best Practice (ERBP) Diabetes Guideline 
Development Group. Dialysis modality choice in diabetic patients with End-
stage Kidney Disease: a systematic review of the available evidence. Nephrol 
Dial Transplant, 2015 Feb;30(2):310-20 
 
BOOK CHAPTERS 
1. First Author of the chapter “Gender at the interface of renal aging:  
physiological and pathological perspectives” in “Principles of Gender-Specific 
Medicine, 3rd Edition”- Elsevier Academic Press (2016) 
2. Co-Author of the chapter “Left Ventricular Hypertrophy in Chronic Kidney 
Disease”, in the “Oxford Textbook of Clinical Nephrology2, 4th Edition- Oxford 
University Press (2015) 
3. Co-Author of the chapter “Kidney and neoplastic disease: an overview with a 
particular interest to interpretation of cancer biomarkers” in “Biomarkers in 
Disease: Methods, Discoveries and Applications”- Springer (2015) 
___________________________________________________________LIST OF PUBLICATIONS 
161 
 
4. Co-Author of the chapter “Overview of Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) as a biomarker in nephrology” in “Biomarkers in Disease: 
Methods, Discoveries and Applications”- Springer (2015) 
5. Unique Author of the chapter “Pulmonary Hypertension in CKD - A New 
Problem Child” in “Cardio-Renal Clinical Challenges”-Springer (2015)  
  
 
  
____________________________________________________________ACKNOWLEDGMENTS 
163 
 
ACKNOWLEDGMENTS 
This thesis would have not been possible without the guidance and the help of some 
“key” persons who, in one way or another, contributed and extended their assistance 
in the preparation, conduction and revision of the studies included in this book.  
First and foremost, my gratitude to Professor Carmine Zoccali and Dr. Giovanni Tripepi, 
whose encouragement, support and advice I will never forget. Their caring and 
guidance provided me with a unique experience of learning, which included many more 
things beyond simply the conduction and interpretation of research findings.  
I want also to express my gratitude to my promotors, Professor Mattace-Raso and 
Professor Sijbrands who offered me invaluable assistance and guidance. Deepest 
gratitude is also due to the members of the doctoral committee and to all the plenary 
committee for the time spent in evaluating my thesis.  
I want also to thank the paranymphs, Claudia and Belinda for helping me to face best 
my doctoral thesis dissertation.  
Finally, last but not least, my special gratitude to my family (Roberta, Aurora and 
Alessandro) for their infinite love and patience through the duration of my studies.  
 
  
  
 
  
_____________________________________________________________ABOUT THE AUTHOR 
165 
 
ABOUT THE AUTHOR 
Davide Bolignano was born in Reggio Calabria (Italy) on October 31th 1980. In 2004 he 
graduated in Medicine (MD) at the University of Messina and in 2009 he obtained the 
specialization in Nephrology, both cum laude. He currently holds a full position at the 
Institute of Clinical Physiology of the Italian National Research Council (CNR) based in 
Reggio Calabria, Italy, as clinical researcher.  In 2012, he was honorary research fellow 
at the Cochrane Renal group (Sydney, Australia) to improving skills in systematic 
reviews, meta-analyses and guideline-making processes. In 2014, he completed the 
Global Clinical Scholars Research Training Program in methods and conduct of clinical 
research at the Harvard Medical School (Boston, US) with a special mention for the final 
thesis. In recognition of his achievements and contributions to the field of nephrology, 
in 2017, he has been awarded the Distinguished Fellow of the European Renal 
Association (FERA). From 2014 he is Head of the Research Unit on Systematic reviews 
and Meta-analysis of the Institute of Clinical Physiology of the CNR. His main scientific 
interests/fields of investigations are the epidemiology and pathophysiology of chronic 
and acute kidney diseases, renal biomarkers and cardiovascular risk. To date, he is 
Author/Co-Author of over 120 scientific peer-reviewed publications indexed on 
Pubmed and several abstracts or invited lectures at various international congresses on 
nephrology, cardiovascular and laboratory medicine.   
 
 
 
 
